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Abstract
Myotonic dystrophy (DM) is a progressive multisystemic genetic disorder which is
inherited as an autosomal dominant trait. There are two subtypes of the disorder, DM
type 1 and DM type 2. DM type1 is caused by an expansion of a CTG repeat located
in the 3' untranslated region of the DMPK gene on chromosome 19q13.3, whereas DM
type 2 is caused by a CCTG expansion in intron 1 of ZNF9 gene located on
chromosome 3q. The mutant RNAs containing the expanded CTG/CCTG repeats
alters the activity of various alternative splicing factors like Muscleblind-like (MBNL)
proteins, which are sequestered in the ribonuclear foci in nucleus by the expanded
mutant transcripts resulting in a number of splicing defects observed in DM patients.
In first part of my thesis, I have assessed the nuclear and cytosolic distribution of
MBNL proteins in both normal and DM cells. In both DM1 and DM2 cells the amount
of nuclear MBNL1 was found to be at least 50% greater than seen in normal cells. In
addition to this, I studied the distribution of MBNL1 protein in nuclear and cytosolic
fractions of DM cells before and after treatment with compounds chromomycin A3,
gemcitabine, IMOX, RO 31-8220 and hypericin which were highlighted in the
primary screen. Treatment with the compounds produced a significant reduction in the
proportion of nuclear MBNL1 compared to DMSO treated cells in DM fibroblast and
myoblasts.
In second part of this thesis I have examined the effect of MBNL1/2 down regulation
on both RNA and MBNL1 foci in DM cells. MBNL1 and MBNL2 double knockdown
resulted in a 40% increase of nuclear RNA foci than observed in scrambled siRNA
treated cells, though a significant reduction was observed in case of MBNL (protein)
foci. Also, MBNL 1 and MBNL2 down regulation did not result in the release of
mutant transcript from the nucleus to the cytoplasm in KB-Telo MyoD (DM) cells as
seen in BpmI restriction polymorphism assay. However, it had a degradative effect on
the mutant DMPK transcript.
1Chapter 1: Introduction
1.1 History of Myotonic Dystrophy
Myotonic dystrophy (DM) is described as the most variable of all human
disorders (Harper, 2001). It is an autosomal dominant inherited disorder of
muscle weakness and wasting. DM is also recognized by other previously used
terms such as myotonia dystrophica, dystrophica myotonia, and myotonia
atrophica. However, the term Myotonic Dystrophy is the most widely used.
In some continental European countries it is still known as Steinerts disease,
in honour of the doctor who first described Myotonic Dystrophy as an
independent disorder. Myotonia refers to certain neuromuscular disorders
characterized by delayed relaxation of skeletal muscles (Gutmann and Phillips,
1991), whereas dystrophy is a name given to muscle disorders in which
muscles shows degeneration of tissue. Myotonic dystrophy combines these two
features, thus its name. The history of myotonia dates back to the 1870s not
with the DM but with the description of myotonia congenita by Dr. Julius
Thomsen. The Danish physician observed an autosomal dominant inheritance
pattern in himself and his family members. Myotonia congenita is therefore
also known as Thomsens myotonia congentia. However the terms myotonia
congentia and congenital muscular dystrophy should not be confused with
congenital Myotonic dystrophy, which is an early childhood form of DM
(Harper, 2001). Table 1.1 gives some of the historical landmarks in the
recognition and breakthroughs of Myotonic Dystrophy. Two research groups,
Steinert and Batten-Gibb, independently described DM as a disease for the first
2time in the year 1909. J.G Greenfield in 1911 documented cataract as a
characteristic symptom of DM after he observed a high occurrence of cataracts
in a large family affected by DM. (Harper, 2001). In 1912, DM was classed as
a multi systemic disorder rather than just a muscular one by Curschmann. In
the year 1960, Vanier recognized the congenital form of myotonic dystrophy,
where he identified the patients problems as dating from birth (Vanier, 1960).
In 1971, the genetic linkage was confirmed between myotonic dystrophy and
two proteins polymorphisms (Lutheran and ABH secretor loci) by Renwick
and Harper (Harper et al., 1972; Renwick et al., 1971). In 1992, after the
identification of unstable DNA sequence in Myotonic dystrophy, the mutation
that caused DM (type 1) was then confirmed as a trinucleotide (CTG) repeat
expansion in a protein kinase gene (Brook et al., 1992; Fu et al., 1992;
Mahadevan et al., 1992). Later in the year 1994, another form of myotonic
dystrophy was recognized as DM type 2 (Ricker et al., 1994). Expanded CCTG
repeats in intron 1 of the ZNF9 gene caused DM2 (Liquori et al., 2001).
DM is an autosomal dominant inherited disorder which affects the muscles and
other organ systems. There is a one in two chance (50%) that the affected
individuals offspring would inherit the disease. DM is the most prevalent form
of muscular dystrophy in adults, which is characterised by progressive muscle
wasting and weakness predominantly occurring in hands, lower legs, face and
neck. Involuntary delayed relaxation or prolonged contraction of skeletal
muscles, cataracts, heart conduction abnormalities and specific sets of
endocrine changes are some of the other common symptoms of DM. (Harper,
2001).
Table 1.1 Histor
3
ical milestones of myotonic dystrophy.
4The severity and the symptoms of the disorder can vary widely from patient to
patient. The effects can be fairly different even among affected individuals of
the same family.
Myotonic dystrophy affects about 1 in 8000 people worldwide (Harper, 2001).
The occurrence of the two forms varies greatly among different geographic and
ethnic groups. In majority of populations, DM1 is more common than DM2.
However, it has been reported that among German and Finland populations,
DM2 may be as prevalent as DM1. (Machuca-Tzili et al., 2005).
51.2 Comparison of clinical features of DM type 1 and DM type2
1.2.1 Muscular dysfunction
DM affects majority of the body systems. Although primarily characterized by
skeletal muscle weakness, muscle wasting predominantly in lower legs, hands,
neck and face. Mostly patients with DM1 and DM2 have clinically
recognisable muscle involvement at the time of diagnosis and often come to
medical attention with muscle dysfunction complaints like myotonia (figure
1.3), muscle weakness or pain (Day et al., 1999; Moxley, 1996; Ricker, 1999)
(Harper, 2001).
There are many similarities and differences in muscle features of DM1 and
DM2. Distal muscle weakness is a predominant symptom in individuals with
DM1, whereas patients with DM2 show more of proximal muscle weakness.
DM1 patients show severe muscle atrophy but in DM2 muscle weakness tends
to be milder and progresses slowly. Ptosis, facial and sternomastoid weakness
are some of the distinct features present in DM1 (figure 1.2) but absent or
inconspicuous in DM2 (Harper, 2001) (Table 1.2).
Myotonia, the hallmark of myotonic dystrophy is involuntary muscle
contraction and delayed relaxation caused by muscle hyperexcitabilty.
Myotonia is present in almost all symptomatic adult patients and is frequently
found in presymptomatic individuals having DM1. Individuals with DM2 show
mild myotonia which rarely causes severe symptoms.
Patients with my
smooth muscle i
different patients
Table 1.2 Mus
2001).
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otonic dystrophy show dysphagia and consti
nvolvement, though there is a substantial
.
cle involvements in DM1 and DM2 (modifi
pation because of
variability between
ed from Harper,
71.2.2 Multisystemic features
DM also affects various other organs of the body such as the eye, heart and the
endocrine system. There has been evidence of series of ocular abnormalities
like cataract, retinal degeneration, ptosis, corneal lesions and extraocular
myotonia. Cataract was first described as an integral feature of myotonic
dystrophy by Greenfield in 1911. Slit lamp examination in nearly all affected
DM1 and DM2 individuals showed posterior subcapsular cataracts, with
distinctive red and green iridescent opacities. Individuals with cataracts may
require lens removal as early as early as second decade of life (Day et al.,
2003). Griffith in 1911, observed cardiac involvement in DM for the first time.
DM shows cardiac conduction defects of varying degrees of severity. Cardiac
involvement leads to conduction abnormalities like arrhythmias, which seems
to occur in DM2 as prominently as in DM1 (Colleran et al., 1997; Nguyen et
al., 1988; Philips et al., 1998), but there is no correlation with repeat length or
severity of skeletal muscle involvement (Lazarus et al., 1999). However it been
documented that the cardiac involvement in patients with DM2 appears to be
more mild than in DM1 (Meola et al., 2002).
Endocrine abnormalities occur in DM2 individuals in form of impaired glucose
tolerance (Day et al., 2003; Savkur et al., 2004). Testicular failure problems
resulting to infertility are also common in both DM1 and DM2, with associated
hypotestosteronemia, elevated FSH levels. Patients with DM1 and DM2 have a
weaker immune system with low levels of both IgG and IgM.
(Hypogammaglobulinemia) (Harper, 2001).
81.2.3 Congenital DM
The presence of large CTG trinucleotide repeats (usually> 2000) results in an
early onset and a more severe disorder called Congenital Myotonic Dystrophy
(CDM). The occurrence of CDM is estimated to be one per 3500 to 16,000
individuals (Wesstrom et al., 1986), though no published population-based
incidence data exist. DM1 leads to a severe congenital condition but the same
has not been observed in case of DM2. Previous data has reported that largest
germline expansions happen at the time of maternal transmission (maternal
bias transmission), although transmission of congenital DM by the father has
been reported (Zeesman et al., 2002). It has also been reported that the length
of CTG repeats could even increase somatically in patients affected with DM
(Martorell et al., 1998). The symptoms for congenital myotonic dystrophy
includes severe generalized muscle weakness, club feet, hypotonia and tented
or 'fish'-shaped upper lip. Mortality in affected infants from respiratory failure
is common.
1.2.4 CNS involvement
Individuals with DM1 and DM2 show central nervous system abnormalities
such as cognitive difficulties, psychological dysfunctions, abnormal behaviour
trait, increased day time sleepiness and neuropsychological alterations. These
changes have been associated with abnormalities in Tauassociated
neurofibrillary tangles observed in brain neurons (Leroy et al., 2006; Oyamada
et al., 2006). However, mental retardation has only been reported in DM1 and
is not recognized in DM2 (Day et al., 2003; Meola et al., 2002). Patients with
CNS abnormalities showed prominent white matter changes on MRI scanning
9and reduced cerebral blood flow in the temporal and the frontal region which
were evident during PET scan (Hund et al., 1997; Meola et al., 1999).
Figure 1. 1 Clinical traits of DM1 and DM2 (taken from Cho and Tapscott,
2007).
DM1 DM2
DM 1 predominant features
Prominent distal muscle
weakness at onset
Distal muscle atrophy at onset
Congenital DM1
Mental retardation
 Hypotonia
Gastrointestinal tract problems
Common features
Myotonia
Weakness and atrophy:
Neck,face,fingers
Cataracts
Cardiac conduction defects
Cognitive dysfunction
Fronting balding
Hypersomnia
DM2 predominant features
Prominent proximal muscle
weakness at onset
Proximal muscle atrophy
Hypertrophy of calf muscles
Comparison of clinical features of DM1 and DM2
Figure 1.2 Ch
Weakness in the
(Hallmark of DM)
10
aracteristic features of myotonic dyst
jaw and in facial muscles is predominant
(Harper, 2001).
rophy patients.
in DM patients.
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Figure 1.3 Grip Myotonia in a myotonic dystrophy patient (taken from
Harper, 2001). Patients with DM have difficulty releasing their grip on objects
(Harper, 2001).
12
1.3 Genetic basis of myotonic dystrophy
1.3.1 The genetic basis of DM type 1
Myotonic dystrophy type 1 is a progressive multi-systemic disorder
characterized by myotonia, skeletal muscle weakness, wasting and pain. In
1992, the genetic mutation responsible for DM1 was identified as CTG repeat
expansion in exon 15 in the 3´- untranslated region of the DMPK gene (Brook
et al., 1992; Fu et al., 1992; Mahadevan et al., 1992). The DMPK gene is
located on chromosome 19q13.3. Previous data has reported that largest
germline expansions happen at the time of maternal transmission., although
transmission of congenital DM by the father has been reported (Zeesman et al.,
2002) but the length of CTG repeats could even increase somatically in people
affected with DM. (Martorell et al., 1998). The children of affected individuals
with gene mutation or with premutations inherit longer repeats than their
parents, the phenomenon known as anticipation (Figure 1.4). The disease
severity is directly proportional to the size of the CTG repeat expansion in the
person. Patients with more than 50 CTG repeats have mild adult-onset DM,
whereas patients with more than 100 to ~1000 repeats have the classical adult-
onset DM. Greater than 2000 or 3000 repeats generally results in the severe
congenital form of the DM. Table 1.3 shows the correlation of phenotype and
CTG repeats in myotonic dystrophy.
13
Phenotype Clinical features CTG repeat
size
1,2
Age of onset
Premutation None 35 to 49 Not applicable
Mild Cataract
Mild myotonia
50 to 150 20 to 70 years
Classical Muscle weakness
Myotonia
Cataracts
Cardiac conduction
defects
Others
~150 to ~1000 10 to 30 years
Congenital Respiratory
abnormalities
Mental retardation
¾ 2000 Birth to 10 years
1. CTG repeat sizes are known to overlap between phenotypes.
2. Normal CTG repeat size is between 5 to 34 repeats.
Table 1.3 Link between phenotype and CTG repeat size in DM1 patients
(de Die-Smulders et al., 1998; Mathieu et al., 1999).
14
Figure 1.4 DM and Anticipation. The image shows a congenitally affected
child with his mother (on right) and grandmother (on left). Features like open-
mouthed appearance can be seen clearly in the child whereas the mildly
affected mother shows reduced facial expression (taken from Harper, 2001).
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1.3.2 The genetic basis of DM2
DM2 is caused by a CCTG repeat expansion in intron 1 of the Zinc finger 9
(ZNF9) gene on chromosome 3q21.3 (Liquori et al., 2001). The number of the
expanded repeats in case of DM2 can range between 75 to 11000 repeats.
However, the normal repeat length is approximately less than 30 CTG repeats
in a normal individual (Liquori et al., 2003). DM2 shows a milder pattern than
DM1 but shows more of proximal muscle involvement than distal muscle
involvement. DM1 can lead to a severe congenital condition but the same has
not been observed in DM2.
1.4 Genetic instability of repeat expansions in DM and UREDs
Several human disorders are now known to be caused by expansion of unstable
repeat sequences, including fragile X syndrome, myotonic dystrophy,
Huntington disease, myotonic dystrophy, spinocerebellar ataxia type 1 and
Friedreich ataxia. All these disorders are covered under a set of genetic
disorders named UREDs (unstable repeat expansion disorders). Mutations in
myotonic dystrophy and fragile X syndrome are due to continuous
intergenerational expansion of trinucleotide repeats. So far more than 30
UREDs have been identified. Most of these disorders are caused by
trinucleotide repeats (TNRs) but it also includes tetranucleotides (Liquori et al.,
2001) (myotonic dystrophy type 2), pentanucleotides (Matsuura et al., 2000)
(spinocerebellar ataxia 10, SCA10). These UREDs can be grouped under five
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major classes according to the location of the repeat expansion in different
regions of their genes:
1. In the coding region of their gene (results in altered protein function)
as in case of glutamine-encoding repeats in polyglutamine and
polyalalanine disorders.
2. Expansions in the 5´-untranslated regions (5´-UTRs) e.g.
spinocerebellar ataxia and fragile X syndrome.
3. In 3´-untranslated regions (3´-UTRs) as observed in DM1 and
Huntingtons disease.
4. In intron regions, as observed in DM 2.
5. Repeat expansions in the promoter regions, as observed in progressive
myoclonic epilepsy 1.
The normal alleles of the genes associated with UREDs, generally contain
stable repeats with either small expanded repeats or long stretches with stable
interruptions (as found observed in fragile X syndrome, which has AGG inserts
in (CCG)n runs in the gene). As the repeat expansions reach a critical threshold
limit, the repeats become highly unstable and lead to particular diseases
(Parniewski and Staczek, 2002). Certain factors like unusual secondary
structures within trinucleotide repeats, DNA-repair models or DNA replication
models might result in this genetic instability but the exact mechanisms of
CTG repeat expansion is still unclear (Harper, 2001).
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1.5 Proposed Molecular Models for Pathogenesis of DM
Three molecular models have been suggested to explain how repeat expansions
in noncoding regions at two different loci cause DM and the mechanism of DM
pathogenesis. The first two models, haploinsufficency of DMPK model and
altered chromatin structure model does not account for all the clinical features
or symptoms seen in DM1 and DM2. However, the RNA dominance mutant
model is considered as the most accepted and probable model which explains
the DM pathogenesis.
1.5.1 Haploinsufficiency of DMPK model
Most dominant disorders are caused by the expression of a malformed protein
with an altered function. So it was not clear how the trinucleotide repeat
expansion which did not affect the protein coding portion of a gene in DM1
resulted in the multisystemic clinical features of the disease (Tapscott, 2000). It
was initially thought that the expanded CTG repeat in the 3´-UTR of the
DMPK gene altered the level of DMPK expression and its protein level which
might be responsible for the multisystemic clinical features of the disease. In
order to test this hypothesis several groups attempted to quantify the expression
of the DMPK RNA from DM tissues and fibroblast cell lines, which all
generated inconsistent and confusing results. Fu et al. (1993) used RT-PCR of
the total RNA extracted from muscle and showed that the DMPK expression
level from the expanded allele was reduced. Two other groups also reported
the absence of mutant DMPK transcripts and reduction in DMPK expression
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level from the normal allele in their studies (Carango et al., 1993; Hofmann-
Radvanyi et al., 1993). However, Mahadevan et al. showed an increase in the
DMPK RNA from DM sources because of increased mRNA stability
(Mahadevan et al., 1993). However more recent reports agreed that the DMPK
mRNA levels were reduced.
In 1996, two groups independently generated DMPK knockout mice in order to
better assess the role of DMPK in DM pathogenesis and to ascertain if some or
all of the symptoms of DM are caused due to reduced levels of DMPK. The
first mouse generated by Reddy et al. (1996) had a targeted disruption of the
mouse dmpk gene. They reported that the homozygous loss of DMPK in mice
resulted in late-onset progressive myopathy that shares some clinical features
with DM. The mice also showed structural abnormalities of skeletal muscle
fibres and weakness. The heterozygous knockout mice generated showed only
a mild phenotype. (Reddy et al., 1996). None of the two mouse models showed
any sign of myotonia, hallmark feature of DM. Jansen et al. (1996) generated a
DMPK knockout mouse in which endogenous DMPK was disrupted. The
mouse showed only mild symptoms and no progressive symptoms were noted.
Jansen et al. (1996) also generated mice which overexpressed the normal
human DMPK transgene. The mice showed cardiac abnormalities but no
skeletal muscle phenotype. When considered together, all these data from
mouse models suggested that DMPK haploinsufficiency alone does not explain
the mutisystemic clinical features of DM. Also there has been no evidence for
DM1 caused by point mutation in the DMPK gene. Additionally, DM2 is
caused by a repeat expansion in another locus (ZNF9), which again cannot be
described by the haploinsufficiency of DMPK gene which is on another locus.
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1.5.2 Chromatin structure model
According to this model the CTG repeat expansion mutation alters the
chromatin structure and affects the expression of DMPK and multiple other
genes in the neighbourhood. It has been known that the repetitive elements in
the genome like the ones at the heterochromatin of telomeres and centromeres
can suppress the expansion of adjacent genes. For example, it was reported that
the genes located adjacent to regions in heterochromatin had an increased
chance of being suppressed in Drosophila, which sometimes resulted in
variegation known as position effect variegation (PEV). So it was reasonable to
believe that the CTG expansion might alter the expression of several other
adjacent genes. Support for this model first came from Wang et al. (1994), who
showed that strong nucleosome positioning signals were created by CTG
repeats which potentially altered the local chromatin structure (Wang et al.,
1994). Work from Otten and Tapscott (1995) showed that the repeat expansion
led to the formation of condensed chromatin structure which may affect
transcription due to limited access of transcription factors or by abnormal RNA
polymerase processing(Otten and Tapscott, 1995). Several other genes have
been mapped around the DMPK gene. These includes the SIX5 (formerly
DMAHP), DMWD (Dystrophia myotonic-containing WD repeat motif), GIPR
(human gastric inhibitory polypeptide receptor gene), FCGRT (4Mb from the
CTG expansion), Symplekin and 20-D7 (Alwazzan et al., 1998; Boucher et al.,
1995; Shaw et al., 1993).
The repeat expansion overlaps not only the 3´ end of DMPK, but with the 5´
end of promoter region of the immediately downstream gene SIX5. SIX5
(formerly DMAHP) belongs to the family of Six family of genes and bear a
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strong resemblance to the Drosophila homeodomain-containing protein gene
sine oculis (SO) that is responsible for eye development and to family of
mouse genes that are implicated in distal muscle development (Winchester et
al., 1999). Cataracts and distal muscle weakness are common symptoms in
DM1, so haploinsufficiency of SIX5 was suggested as possible cause for the
formation of cataracts observed in DM1 patients. Several studies have shown
that there was a remarkable reduction in SIX5 gene expression in the DM1
patients compared to normal controls (Alwazzan et al., 1999; Klesert et al.,
1997; Thornton et al., 1997).
SIX5 knockout mice models were created independently by two research
groups (Klesert et al., 2000; Sarkar et al., 2000). Both the mice models
developed ocular cataracts. This suggested that reduced SIX5 expression
contributes to cataract phenotype, and was convincing data to account for the
function of adjacent genes in DM pathogenesis. However, the cataracts
observed in SIX5 knockout mouse didn't have characteristic iridescent opacities
observed in DM patients.
DMWD gene which is located immediately upstream of DMPK gene is shown
to be expressed strongly in the brain and testis. Alwazzan and colleagues
(1999) reported there was 20-50% reduction in the level of RNA from the DM-
linked allele of DMWD in the cytoplasmic fraction but there was no reduction
in the nuclear fraction. It was suggested that haploinsufficiency of DMWD may
be responsible for mental retardation and testicular symptoms seen in DM1
patients and may contribute to DM1 pathogenesis.
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However, the DM2 locus (ZNF9 and neighbouring genes) is on an entirely
different chromosome therefore the genomic arrangement neighbouring the
repeat is entirely different from DM1; thus the chromatin structure model is not
able to explain the phenotypes observed in both DM1 and DM2.
1.5.3 RNA dominance mutant model
The demonstration that the haploinsufficiency of DMPK and other
neighbouring genes does not fully explain the multisystemic clinical features of
DM leads to the possibility of a RNA dominant gain-of-function model. This
model suggests that CUG/CCUG repeats exert a toxic effect that disrupts
splicing and other possible functions. Support for this model first came from
Taneja et al. (1995). They used the fibroblasts and muscle biopsies from
myotonic dystrophy patients and normal controls to detect the localization of
DMPK transcripts using oligonucleotides probe (10 repeats of CAG) labelled
with a fluorochrome. The expanded transcripts were seen to accumulate in the
nucleus as bright foci in fibroblasts and muscle biopsies from DM patients but
not in normal controls (Davis et al., 1997; Taneja et al., 1995).
Davis et al. (1997) also showed that the mutant transcripts formed stable
clusters that were tightly linked to the nuclear matrix. They used northern
blotting and In situ hybridisation to analyse the DMPK transcripts in
differentiated cultured myoblasts. In 1997 Hamshere et al. used allele specific
RT-PCR to analyse sub-cellular fractionation (RNA from cytoplasmic and
nuclear fractions) from DM fibroblast cells. They reported the nuclear retention
of the transcripts from the expanded DMPK alleles and their absence from the
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cytoplasm of the DM cells. Further analysis also suggested that the nuclear
retention of transcripts from the expanded DMPK alleles occurs above a
critical threshold frequency between 80 and 400 CTGs (Hamshere et al., 1997).
In 1999, Amack and colleagues showed that mutant DMPK 3´-UTR mRNA
along with CUG (200) inhibited myogenic differentiation in C2C12 mouse
myoblasts model system by reducing the levels of MyoD. They also
demonstrated that the expression of 57 CTGs in mutant DMPK 3´-UTR alone
was able to form foci (ribonuclear spots) (Amack et al., 1999).
Evidence that there is a common underlying pathogenic RNA mechanism
between DM1 and DM2 came from the studies of Liquori et al. (2001). They
used in situ hybridisation to demonstrate that CCUG-containing RNA can also
form foci in DM2 muscle. These studies gave further evidence that RNA gain-
of-function played an important role in DM pathogenesis.
The direct support for the pathogenic effect of the repeat expansion was
reported in a mouse model developed by Mankodi et al. (2000). They
generated transgenic mice by inserting (CTG250) repeat expansion into the 3´
end of the human skeletal actin gene (HSA
LR
), a transcript unrelated to the
DM1 and DM2 loci. The mouse showed myotonia and myopathic features
characteristic of DM. The mouse model also showed MBNL1 sequestration
and mis-splicing of multiple other transcripts like Clcn1, Mbnl1, Ldb3/Cypher
and Serca1 (Mankodi et al., 2000).
Seznec et al. (2001) also developed a mouse model which expressed 300 CTG
repeats in the context of the human DM1 locus (>45Kb). This mouse showed
ribonuclear foci in various tissues like skeletal muscle and heart. It displayed
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myotonia, progressive muscle weakness and muscle histopathology consistent
with that seen in DM1 patients. It also showed abnormal distribution of tau
protein isoforms as seen in DM patients (Seznec et al., 2001).
In 2006, Mahadevan and colleagues used an inducible mouse model to
demonstrate the reversible nature of RNA toxicity. They used the tetracycline
(Tet) inducible system to generate mice with the wild type (CTG)5'03.ƍ
UTR and the mutant (CTG)200'03.ƍ8757UDQVJHQHH[SUHVVLRQLQPXWDQW
(CTG)200 '03. ƍ 875 UHVXOWHG LQ IRFL IRUPDWLRQ DQG 0%1/ SURWHLQ
sequestration but no RNA foci or MBNL sequestration was seen in the case of
wild type (CTG)5 '03. ƍ 875 7KH PRXVH ZLWK WKH VKRUW UHSHDW &7*5
developed profound myotonia and cardiac conduction abnormalities which is
not analogous to symptoms seen in unaffected human individuals or humans
carrying 5 CTGs repeats. So this limits its application in therapeutic assays.
The experimental studies mentioned above suggested that repeat expansion
(CTG/CCTG) in mutant RNA leads to toxic gain-of function but the reason
transcripts with expanded CUG/CCUG repeats caused the multiple features of
DM came from the hypothesis of protein sequestration (Timchenko et al.,
1996). Various studies have reported that expanded CUG and CCUG-
containing transcripts in DM1 and DM2 respectively sequester certain RNA-
binding proteins into nuclear foci (Michalowski et al., 1999). RNA-binding
proteins play a vital role in post-transcriptional control of RNAs, such as RNA
metabolism, nucleocytoplasmic transport, splicing, polyadenylation and
translation. Sequestration and depletion of these transcription factors from their
active sites, prevents these proteins from performing their normal cellular
functions. Two families of proteins have been identified which cause the RNA
24
transdominant effect. The first one is the CUG-BP1 (CUG binding protein) , it
belongs to a family of RNA binding protein known as CELF (CUG-BP- and
ETR-3-like factor) family of RNA processing factors, which is responsible for
alternative splicing of different transcripts (Ladd et al., 2001).The second is the
Muscleblind-like proteins (further discussed in section-1.7.2). Disrupted
function of RNA-binding proteins such as CUG-BP1, MBNL and hnRNPs
leads to a number of splicing defects observed in DM patients which results in
the occurrence of disease symptoms.
1.6 Spliceopathy/ Aberrant Alternative Splicing in DM
1.6.1 Alternative splicing
RNA splicing is a regulated post-transcriptional process that occurs prior to the
translation of the mRNA. In this process the coding regions or exons are either
retained or excluded to generate different sets of mRNAs, which further result
in several protein isoforms from a single gene. Alternative splicing has an
effect on most of genes in the human genome; therefore misregulation of RNA
splicing has been linked with many human disorders (Cooper et al., 2009;
Wang and Cooper, 2007). It has been reported that the expanded CTG/CCTG
repeats sequester various RNA binding proteins, which are crucial for normal
alternative splicing. Thus the depletion or sequestration leads to aberrant
alternative splicing of many other gene transcripts related to DM which then
causes the multisystemic features of the disease (Mankodi et al., 2002).
Misregulation of splicing has been reported in DM patients cells in many gene
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transcripts like chloride channel 1, insulin receptor, cardiac troponin T. Some
of the typical splicing alterations are discussed below:
1.6.1.1 Chloride channel 1 (Clc1)
Clc1 is a voltage-gate chloride channel encoded by the CLCN1 gene (also
named CLC1). The CLCN1 gene belongs to a family of genes called CLCN
(chloride channels, voltage-sensitive). These channels are responsible for
transporting negatively charged chlorine atoms (chloride ions) across cell
membranes. They play a key role in stabilizing the resting membrane potential
and help in regulating electrical excitability in skeletal muscle (Dutzler et al.,
2002). More than 60 CLCN1 mutations have been identified in people with
myotonia congenita (MC). Most of these mutations have been associated with
the recessive form of MC (Becker disease) and with the dominant form
(Thomsen disease) (Grunnet et al., 2003; Sasaki et al., 1999; Sasaki et al.,
2001).
A predominant and a classic feature of both DM1 and DM2 is myotonia, which
is caused by involuntary repetitive firing of action potentials that delays
skeletal muscle relaxation following voluntary muscle contraction (Harper,
2001). Mankodi and colleagues (2000, 2002) used skeletal muscle from a
transgenic mouse to show that expression of expanded CUG repeats reduces
the transmembrane chloride conductance to levels thought to be enough to
cause myotonia in DM patients (Mankodi et al., 2002). It has been
demonstrated that loss of CLCN1 mRNA and protein observed in DM1 muscle
samples was due to aberrant splicing of CLCN-1, the main chloride channel in
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muscle. Misplicing of CLCN1 involves retention of intron 2, which contains a
premature stop codon, or inclusion of two novel exons between exon 6 and
exon 7 (Charlet et al., 2002). Charlet and colleagues (2002) showed that CUG-
BP is elevated in DM1 striated muscle and binds to the CLCN1 pre-mRNA,
and overexpression of CUG-BP in transfected cells (normal cells) reproduces
the aberrant pattern of CLCN1 splicing, similar to that observed in DM1
skeletal muscle.
Similar splicing alterations were observed in muscle tissue from DM1 and
DM2 patients, suggesting a common pathogenic mechanism for both types of
disease (Charlet et al., 2002; Mankodi et al., 2002).
1.6.1.2 Insulin receptor (IR)
The IR LV D KHWHURWHWUDPHU VWUXFWXUH PDGH XS RI WZR ĮVXEXQLWV DQG WZR ȕ
subunits, encoded by a single gene INSR. Binding of insulin to the extracellular
ĮVXEXQLW OHDGV WR DXWRSKRVSKRU\ODWLRQ RI WKH LQWUDFHOOXODU ȕ VXEXQLW 7KHUH
are two isoforms of insulin receptor because of alternative splicing of the 36
QXFOHRWLGHV H[RQ  RI WKH ĮVXEXQLW ,VRIRUP ,5$ ODFNLQJ H[RQ  DQG
isoforms IR-B (including exon 11). Expression of these two isoforms is tissue-
specific (Moller et al., 1989; Seino and Bell, 1989). The isoforms lacking exon
11 (IR-A) has higher affinity for insulin than the isoforms including exon 11
(IR-B). Isoform IR-B is predominantly expressed in adipose tissue, liver and
skeletal muscle, all of them responsible for glucose homeostasis (Moller et al.,
1989; Mosthaf et al., 1990).
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A common clinical feature in both DM1 and DM2 patients is insulin
resistance. Insulin resistance is a condition in which cells fail to respond to the
normal actions of the hormone insulin. It has already been shown that the
reduced insulin response in skeletal muscle predisposes DM patients to
diabetes. Savkur and colleagues (2001) demonstrated that alternative splicing
of the insulin receptor (IR) pre-mRNA is aberrantly regulated in DM1 skeletal
muscle cultures (Savkur et al., 2001), which resulted in inappropriate
expression of the IR-A isoform (lacking exon 11) in skeletal muscle. They also
showed that there was an increase in steady state levels of CUG-BP in skeletal
muscle of DM1 patients and overexpression of CUG-BP also induces a switch
in the splice form, towards IR-A in normal cultured cells. This strongly
suggested that CUG-BP mediates this alternative splicing switch by binding to
an intronic element upstream of the alternatively spliced exon 11. Thus,
increase in CUG-BP levels was considered as the primary determinant for the
misregulation of Insulin receptor (IR) (Savkur et al., 2001).
In addition to this, it has been found that the same insulin receptor splicing
alterations occur in muscle biopsies from patients from DM2 (Savkur et al.,
2004).
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1.6.1.3 Cardiac Troponin T (cTNT)
In humans, the protein Troponin T type 2 (cardiac) or TNNT2, is encoded by
the TNNT2 gene. Cardiac troponin T is a thin filament contractile protein. It is
the tropomyosin-binding subunit of the troponin complex, which is located on
the thin filament of striated muscles and regulates muscle contraction.
Mutations in this gene in humans are responsible for causing familial
hypertrophic cardiomyopathy, and can also cause dilated cardiomyopathy
(Kamisago et al., 2000; Seidman and Seidman, 2001). Transcripts for TNNT2
undergo alternative splicing of 15-bp (exon 4) and 30-bp (exon 5) mini-exons
which results into multiple tissue-specific isoforms. Exon 5 is included in
transcripts produced during the early development of heart and skeletal muscle,
but not in adult heart.
In 1998, Phillips and colleagues analysed cardiac tissues from DM1 patients
and demonstrated that there was a shift to the embryonic isoforms by
preferential inclusion of exon 5 in the adult tissues (Philips et al., 1998). This
aberrant splicing pattern was due to the binding of CUG-BP to the human
cardiac troponin T (cTNT) pre-mRNA, resulting in a transdominant effect and
suggesting a role in the regulation of its alternative splicing. To confirm this,
transgenic mice overexpressing CUG-BP1 in heart and skeletal muscle, two
tissues affected in DM, was generated. The mice showed disrupted splicing for
cTNT, CLCN1 and Mtmr1 (Ho et al., 2005a). Cardiac Troponin T was the first
pre-mRNA shown to be aberrantly spliced in DM1 (Philips et al., 1998).
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1.6.1.4 Tau
Tau proteins play an important role in stabilizing microtubules. They are
abundant in neurons of the CNS but are also expressed at very low level in
CNS astrocytes and oligodendrocytes (Shin et al., 1991). Tau protein assists
with the formation and stabilization of microtubules by binding to them. But
when Tau proteins become hyperphosphorylated, it is unable to bind and leads
to the disintegration of microtubules. The unbound tau clumps together to form
a complex known as Neurofibrillary Tangels (NFTs), which then interfere with
various other normal intracellular functions. NFTs presence is found in several
neurodegenerative diseases like Alzheimers disease, frontotemporal dementia
with Parkinsonism linked to chromosome 17 and other conditions known
collectively as tauopathies. Six tau isoforms have been identified in human
central nervous system. These isoforms are a result of alternative splicing in
exons 2, 3 and 10 of the tau gene. A specific set of tau isoforms are aggregated
in the neocortex and subcortical nuclei in DM1 patients as reported by different
research groups (Kiuchi et al., 1991; Mitake et al., 1989; Vermersch et al.,
1996). In 2001 Sergeant and colleagues showed that there were splicing
alterations in the microtubule-associated tau pre-mRNA in CNS tissue from
DM1 patients (Sergeant et al., 2001). They also observed lower amounts of tau
isoforms containing the exon 2 and exon 3 at both mRNA and protein levels,
compared with controls. Role of tau in DM was also validated by using a
mouse model which expressed CTG repeats in DMPK 3´ -UTR. Like DM1
patients, the transgenic mice showed abnormal expression of tau in brain
(Seznec et al., 2001).
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1.6.1.5 Myotubularin-related protein 1 (MTMR1)
The MTMR1 gene belongs to a conserved family of phosphatase genes
including 14 members in human, mainly MTM1 and MTMR1-13. Alternative
splicing of MTMR1, produces three major isoforms A, B and C. During muscle
differentiation, the expression of MTMR1 is developmentally regulated by
alternative splicing of two fetal isoforms A and B, which switches to the adult
isoforms C in adult skeletal muscle and cardiac muscles during development
(Buj-Bello et al., 2002). No mutations in the MTMR1 gene have been linked
with human diseases so far, but aberrant splicing of MTMR1 pre-mRNA has
been reported in differentiating muscle cell cultures in congenital DM1
patients. Buj-Bello and colleagues (2002) observed that there was a significant
reduction of the normal muscle adult C isoforms, increased levels of the fetal A
and B isoforms and the presence of a new aberrant G isoforms containing
novel exon 2.2 in skeletal muscle biopsies of congenital DM1 patients and in
differentiating muscle cell cultures.
Ho et al. (2005) also reported that the transgenic mice overexpressing CUG-
BP1 showed disrupted splicing of MTMR1 gene, consistent with that observed
in DM heart and skeletal muscle. Analysis of splicing by RT-PCR indicated
that the mice expressed more of fetal A and B isoforms, compared to the wirld
type mice, which expressed more of adult normal C isoforms (Ho et al.,
2005a).
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1.6.1.6 Ryanodine receptor (RyR) and Sarcoplasmic/endoplasmic
reticulum Ca
2+
-ATPase (SERCA)
Ryanodine receptor 1 (RyR1) and sarcoplasmic/endoplasmic reticulum Ca
2+
-
ATPase (SERCA), the two sarcoplasmic reticulum (SR) proteins are
responsible for regulating intracellular Ca
2+
homeostasis in skeletal muscle
cells (Kimura et al., 2005). There are multiple isoforms of ryanodine receptors
in mammals. RyR1- primarily expressed in skeletal muscle. RyR2 is expressed
in heart muscle and RyR3 is expressed more widely, but particularly in the
brain. The expression of RyR1 isoform is regulated both developmentally and
in a tissue specific manner (Futatsugi et al., 1995). In case of SERCAs, there
are 3 major paralogs, SERCA1, SERCA2 and SERCA3. They are all expressed
at different levels in different cell types. Alternative splicing for transcripts
from these genes is regulated developmentally and in tissue specific manner.
This results into isoforms that differ in their C-terminal region (MacLennan et
al., 1997). SERCA1a, which is an adult isoform and SERCA1b, which is a
neonatal isoform are primarily expressed in fast-twitch (type2) skeletal muscle
(Wuytack et al., 1992). SERCA2a is expressed in slow twitch (type1) skeletal
and cardiac muscles, but SERCA2b expression is more extensive. SERCA3 is
found in many non-muscle tissues at different levels (Lytton et al., 1992).
Several splice variants for RyR1 has been described by Futatsugi et al.(1995).
The variant ASI (-), which lacks exon 70 and a splice variant ASI (+), which
has the exon 70. Kimura and colleagues (2005) reported that the fetal variant,
ASI (-) of RyRI which lacked the exon 70 was significantly increased in
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skeletal muscles from DM1 patients and the transgenic mouse model (HSA
LR
)
(Kimura et al., 2005).
In the case of the other SR protein, SERCA, the proportion of SERCA1b (-
exon 22) was significantly elevated in DM1 muscles compared to control. This
was consistent to what was observed in transgenic mouse model of DM1
(HSA
LR
). Data from these studies suggested that aberrant splicing of RyR1 and
SERCA1 mRNAs played a role in misregulation of intracellular Ca
2+
homeostasis in DM1 muscle (Kimura et al., 2005).
1.6.1.7 Fast Skeletal Troponin T (TNNT3)
Kanadia and colleagues (2005) reported aberrant splicing of TNNT3 in adult
DM1 muscle. This was further verified by reporting the presence of fetal (F)
exon isoform in muscleblind-like knock out mouse model (Mbnl
ǻ(ǻ(
)
(Kanadia et al., 2003).
1.7 Role of RNA-binding proteins in DM
RNA-binding proteins play an important role in many cellular processes and
functions. They are involved in many post-transcriptional activities like
splicing, polyadenylation, mRNA stabilization and localization and translation.
The two main families of RNA-binding proteins implicated in DM
pathogenesis are MBNL and CELF proteins. hnRNP H, another RNA-binding
protein, has also been shown to be implicated in DM pathogenesis.
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1.7.1 CUG-BP1 and pathogenesis of DM
CUG-BP was the first protein to be reported and analysed by Timchenko and
colleagues in 1996. Bandshift analyses using cell extracts of HeLa cell,
fibroblasts and myotubes were used as protein source to identify CUG-BP.
CUG-BP protein was found to specifically bind to triplet repeats (CUG)
present in DMPK mRNA, so was termed CUG-BP (CUG binding protein).
Two isoforms of CUG-BP were identified; CUG-BP1 and CUG-BP2, both are
isoforms of a novel heterogeneous nuclear ribonucleoprotein (hNab50)
(Timchenko et al., 1996). CUG-BP is a member of the CELF (CUG-BP1 and
ETR-3-like factors) family of RNA-processing factors that regulates alternative
splicing (Ladd and Pliam, 2001). Six CELF (also known as BRUNOL) genes
have been identified in humans by screening human EST databases (Ladd et
al., 2001; Ladd et al., 2004). All six CELF proteins were reported to regulate
pre-mRNA alternative splicing and two of them (CUG-BP1 and ETR-3/CUG-
BP2) were also involved in cytoplasmic RNA-associated functions (Lu et al.,
1999).
The CELF family proteins can be sub grouped into two groups, first group
consisting of CUG-BP and ETR-3 (which are 78% identical amongst each
other) and a second group consisting of three novel proteins CELF3, CELF4
and CELF5 (CELF3 has 60.8 % sequence similarity with CELF4 and CELF5
has 63.8% sequence similarity with CELF4).
The in vivo experiments involving CUG-BP/hNab50 showed that CUG-BP
interacts with mRNAs and are involved in the processing or transport of many
other transcripts. It was initially thought that CUG-BP proteins were
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sequestered by the expanded CUG repeats in DMPK RNA just like MBNL
proteins. However, it was reported by Michalowski and colleagues (1999) that
CUG-BP is not sequestered by RNA containing the expanded CUG repeats.
They used electron microscopy to examine the structure of CUG75-130 repeat
containing RNA and CUG-BP together and reported that binding of CUG-BP
was only at the base of the RNA hairpin and not on the hairpin stem
(Michalowski et al., 1999). It was postulated that the binding of CUG-BP
protein was not proportional to the CUG repeat length and it was also observed
in yeast three-hybrid system that it preferentially binds to the UG motifs rather
than CUG repeats. Furthermore, Fardaei and colleagues (2001) reported using
indirect Immunofluorescence and GFP tagged proteins that the CUG-BP does
not colocalize with the expanded CUG repeats in DM1 cells (Fardaei et al.,
2001).
As reported in previous studies, two phosphorylated forms of CUG-BP- a
hyperphosphorylated form (CUG-BP1) and a hypophosphorylated form (CUG-
BP2) exist (Roberts et al., 1997). CUG-BP is in fact a substrate for DMPK. An
increase in the level of hypophosphorylated form (CUG-BP2) in the nucleus
was observed as result of the reduced levels of DMPK protein in DM patients
and DMPK knockout mice (Roberts et al., 1997).
In a recent study, it was shown that the expression of DMPK-CUG-repeat
RNA activates protein kinase C (PKC), which leads to CUG-BP1
hyperphosphorylation and increased CUG-BP1 steady state levels in DM1
(Kuyumcu-Martinez et al., 2007).
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Several studies have pointed towards a gain of CUG-BP1 activity in DM1.
They have all reported an increase in CUG-BP1 steady state levels in DM1
myoblasts, heart tissues and skeletal muscle (Dansithong et al., 2005; Savkur et
al., 2001; Timchenko et al., 2001). CUG-BP1 is known to regulate alternative
splicing of pre-mRNAs like cTNT, IR and Clc1, which are aberrantly spliced
in DM1 striated muscles (Charlet et al., 2002; Philips et al., 1998; Savkur et al.,
2001). To test whether increase in CUG-BP1 steady state levels was sufficient
to cause the misregulation of alternative splicing of specific transcripts in DM,
Ho and colleagues (2005) generated a transgenic mice overexpressing CUG-
BP1 (MCKCUG-BP1) in heart and skeletal muscles. These mice showed
aberrant splicing for TNNT2, MTMR1 and CLCN1, consistent with that
observed in DM. They also showed histological abnormalities like chains of
central nuclei and degenerating fibers, resembling congenital DM1 (Ho et al.,
2005a). Timchenko et al. (2004) generated CELF1 overexpressing lines
(CUGBP1-TR). They reported that there was a significant increase of MEF2A
and p21 levels compared to wild type controls, in CELF1 overexpressed
CUGBP1-TR lines. These lines also displayed delayed myogenesis and growth
retardation that correlated with the level of CELF1 upregulation (Timchenko et
al., 2004).
In addition, to these CUG-BP1 overexpression models, there have been two
recent mouse models which showed inducible tissue- specific expression of
RNA containing CUG repeats in the context of the DMPK 3´-UTR
(Mahadevan et al., 2006; Orengo et al., 2008; Wang et al., 2007) . To better
study the role of CUG-BP1 in spliceopathy in DM pathogenesis, Mahadevan
and colleagues (2006) generated an inducible model overexpressing the DMPK
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3´-UTR with CTG5 or CTG200 repeats (figure1.5, c). The mice with CTG200
repeats showed RNA foci and MBNL1 sequestration. The mice with CTG5
repeats showed no RNA foci or MBNL1 sequestration but it displayed
profound myotonia and heart and skeletal muscle abnormalities on transgene
expression (Mahadevan et al., 2006). Unlike HSA
LR
mice, the splicing defects
in GFP-DMPK-(CTG)5 mice were associated with CELF1 upregulation
(Mahadevan et al., 2006).
Wang et al. (2007) and Orengo et al. (2008) both used the inducible Cre-Lox
system to produce tissue-specific expression of expanded CUG repeats (figure
1.5, b). Orengo and colleagues (2008) suggested that the increased CUG-BP1
levels were associated with aberrant alternative splicing of CLCN1 (inclusion
of the fetal exon 7a which contains a premature stop codon), SERCA1
(exclusion of exon 22) and CYPHER (inclusion of exon 11) in the mouse
model (EpA960) after tamoxifen-induced transgene expression (Orengo et al.,
2008). Unlike HSA
LR
mice, which didn't show any CELF1 upregulation or
muscle weakness, the EpA960 mice (figure1.5, b) showed CUG-BP1
hyperphosphorylation and upregulation after the transgene expression. This
suggested that the genomic context of CTG expansion may be contributing to
CELF1 upregulation, which then results into misplicing of CUG-BP1
dependant transcripts.
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Figure 1.5 Schematic representation of CTG-expressing transgene
constructs (modified from Mario Gomes-Pereira, 2011). A) HSA
SR
and
HSA
LR
transgenic mice carrying a fragment of human skeletal actin (HSA)
gene with 5 CTG and 200 CTG repeats inserted in its final exon respectively.
B) Inducible EpA mice carrying human version of DMPK exon 15, with (960
CTGs) or without repeats. C) GFP-DMPK-(CTG)n mice which expresses a
GFP transcript fused to the DMPK 3´-UTR containing 5 or 200 CTG repeats.
B.
C.
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1.7.2 MBNL and pathogenesis of DM
Another family of RNA-binding proteins, one which bind with high affinity to
RNAs containing the expanded CTG repeats in a size-dependent manner, is
Muscleblind-like protein (MBNL), a mammalian homologue of Drosophila
muscleblind protein (Mbl) which is necessary for development of muscle and
differentiation of photoreceptor cells in Drosophila (Miller et al., 2000).
Drosophila Mbl proteins contain two tandem zinc finger (TZF) motifs,
members of the zinc finger family of nucleic acid binding motifs. These zinc-
finger motifs presumably confer on Mbl the ability to bind to their RNA targets
(Begemann et al., 1997; Miller et al., 2000). Unlike Drosophila Mbl protein,
human MBNL protein has four tandem zinc finger (TZF) motifs instead of two.
Muscleblind-like proteins in humans are encoded by three different genes,
which are known as MBNL1 (formally MBNL), MBNL2 (MBLL) and MBNL3
(MBXL), located on chromosomes 3, 13 and X respectively (Fardaei et al.,
2002; Miller et al., 2000). It has been shown that MBNL1 is primarily
expressed in muscle and heart, unlike MBNL2, which shows a similar level of
expression across all tissues like heart, brain, lung, placenta, liver, skeletal
muscle and kidney. MBNL3 has a strong expression in placenta (Fardaei et al.,
2002). All three MBNL proteins have been shown to co-localize with expanded
CUG/CCUG repeats RNA foci in vivo (Fardaei et al., 2002; Mankodi et al.,
2001; Miller et al., 2000). Reduction of MBNL proteins, due to sequestration
by the RNA containing expanded CTG/CCTG repeats may account for some of
the pathological features of DM. In support for this hypothesis, Kanadia et al.
(2003) generated a mouse knockout model (MBNL
ǻ(ǻ(
). The mouse showed
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myotonia, cataracts and misregulation of splicing observed in DM1 and DM2.
Consistent with the hypothesis that MBNL1 sequestration causes aberrant
splicing of specific RNAs, Kanadia et al. (2006) used adeno-associated virus
(AAV) - mediated transduction to overexpress MBNL1 protein. They showed
that overexpression of MBNL1 in transgenic HSA
LR
mice rescued the
myotonia and splicing defects of CLCN1, CYPHER/Ldb3, SERCA1 and
TNNT3 (Kanadia et al., 2006). More recently Chamberlain and colleagues
(2012) generated the first transgenic MBNL1 overexpression mouse model to
check the safety and therapeutic potential of MBNL1 overexpression. They
reported that the high levels of MBNL1 overexpression was well accepted by
skeletal muscle and it ameliorated skeletal muscle myopathy (Chamberlain and
Ranum, 2012).
MBNL1 protein has been shown to play a main role in DM pathogenesis in
various studies. Dansithong and colleagues (2005) tested the role of MBNL
proteins in the maintenance of DM1 foci integrity by down regulating the
levels of MBNL1 and MBNL2 in DM1 myoblasts using siRNAs. They
reported that depletion of MBNL1 protein resulted in reduction of foci by
nearly 70 %, ~25% reduction in foci number in case for MBNL2 depletion and
together (MBNL1 and MBNL2 depletion) it resulted in reduction of foci
number by 80% (Dansithong et al., 2005). Loss of MBNL1 function due to its
sequestration has been implicated in misregulated splicing of many transcripts
like CLCN1, IR and cTNT which leads to the disease symptoms like myotonia,
insulin resistance and cardiac conduction abnormalities in patients with DM
(Charlet et al., 2002; Dansithong et al., 2005; Ho et al., 2004) but it was not
clear if the phenotype was caused by direct or indirect effects on splicing. To
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test this, Ho et al. (2004) used siRNA to downregulate MBNL1 levels in HeLa
cells. Analysis revealed that depletion of endogenous MBNL1 altered
alternative splicing of cTNT and IR (Ho et al., 2004). Furthermore, it had
already been shown that overexpression of MBNL1 and MBNL2 played a
predominant role in the rescue of IR splicing defects in DM1 myoblasts
(Dansithong et al., 2005).
But there are studies which indicate that sequestration of MBNL proteins alone
cannot account for all clinical features seen in the DM. A study performed by
Ho et al. (2005) showed that both CUG and CAG RNA repeats were able to
form foci that contain both exogenously expressed GFP-MBNL1 and
endogenous MBNL1, but only CUG repeats altered splicing of cTNT and IR
transcripts (Ho et al., 2005b).
A MBNL1 knockout mouse model was generated by Kanadia and colleagues
(2003) which mimicked the DM1 situation where MBNL1 protein is
sequestered and is functionally unavailable for normal use. The mice displayed
myotonia (CLCN1 aberrant splicing and ClC-1 protein reduction), cataracts and
missplicing of certain other transcripts. However, muscle weakness was not
detected in this model which results from different mechanisms, like CELF
upregulation (Kanadia et al., 2003). Thus, some features of DM phenotype may
not result from loss of MBNL1 function alone and other factors might be
involved in DM pathogenesis.
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1.7.3 MBNL and CUG-BP1 proteins are antagonistic regulators of
alternative splicing
The expanded CUG repeats have a trans-dominant effect on alternative splicing
regulation through at least two RNA-binding proteins: Muscleblind-like 1
(MBNL1) and CUG-BP1. These proteins are antagonistic regulators of splicing
events that are misregulated in DM1. In DM normal developmental splicing
events are disrupted which results in expression of fetal protein isoforms
instead of adult isoforms in adult tissues. It has been shown that the MBNL
levels are reduced due to sequestration by expanded CUG repeats RNA and
steady state levels of CUG-BP1 are increased in DM cells. Loss of MBNL1
function and CUG-BP1 elevation has been implicated in misregulated splicing
of pre-mRNAs like IR and cTNT which leads to the disease symptoms like
insulin resistance and cardiac conduction abnormalities in patients with DM
(Ho et al., 2004; Lin et al., 2006; Philips et al., 1998; Savkur et al., 2001).
CUG-BP1 induces inclusion of both human and chicken cTNT exon5 and exon
skipping of human IR exon 11 whereas, MBNL proteins promotes exon
skipping of human and chicken cTNT exon5 and inclusion of human IR exon
11 (Charlet et al., 2002; Ladd et al., 2001; Philips et al., 1998; Savkur et al.,
2001). The antagonism is not due to the direct competition for the same
binding site, but both MBNL and CUG-BP1 proteins recognize discrete cis-
acting parts in human and chicken cTNT (Ho et al., 2004). CUG-BP1 can
regulate splicing of minigenes even if there is a mutation in MBNL1-binding
site. Likewise, MBNL can regulate splicing of minigenes with CUG-BP1-
binding site mutation that block CUG-BP1 responsiveness. This suggest that
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MBNL and CUG-BP1 proteins act independently and they don't have a direct
competition for the common binding site (Ho et al., 2004).
The RNA dominance model describing the pathogenesis of myotonic
dystrophy is summarized in Fig. 1.6
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Figure 1.6 RNA toxic gain of-function for DM (modified from Diane and
Tapscott, 2007). The RNA dominance mutation model proposes that the
expanded CTG repeats results in a toxic gain of function at the RNA level by
disrupting the activities of RNA-binding proteins implicated in regulating
alternative splicing and mRNA translation. Alteration of various RNA-binding
proteins such as MBNL1-3, CUG-BP1 and hnRNP H leads to misregulation of
many developmentally regulated transcripts, which causes the symptoms in
DM.
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1.8 Possible Targets for Therapeutic Intervention in DM
Currently there is no treatment for either form of DM. Molecular therapeutic
strategies for DM1 can be directed specifically at the level of RNA or protein.
There have been many publications involving biochemical and
oligonucleotides based therapy directed against molecular effects of repeat
expansion. They aimed at either correcting of aberrant splicing (Wheeler et al.,
2007) or disrupting the interaction between MBNL and the repeats (Arambula
et al., 2009; Gareiss et al., 2008; Mulders et al., 2009; Pushechnikov et al.,
2009; Warf et al., 2009; Wheeler et al., 2009). Also there have been studies
which utilized the use of cell based assays in conjunction with fluorescent
splicing reporters for compound screens (O'Leary et al., 2009; Orengo et al.,
2006).
Our own lab designed and developed cell-based assays that were utilized for
screening molecules and compounds for DM therapy. These assays allowed the
screening of thousands of small molecules and compounds on large scale in
High Throughput Screens (HTS) to identify compounds that eliminate nuclear
foci and may have potential for further development as DM therapies (Ketley
et al., 2013). The initial primary screen analysed compounds from 3 different
libraries. 13200 compounds were screened from a Chembrige Diverset library,
2724 compounds from the NPC library and 80 kinase inhibitors and 33
phosphatase inhibitors from Enzo Life sciences. Table 1.4 shows the number of
compounds screened as part of primary screening and the positive hits which
were taken forward to secondary assays.
Table 1.4 Show
taken forward t
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s the number of compounds screened an
o the secondary and tertiary assays (Ketley
d the numbers
et al., 2013).
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1.9 Aim of project
Myotonic dystrophy (DM) is the most common adult-onset muscular dystrophy
that affects the muscles and various other body systems. Strong evidence
supports a pathogenic RNA dominance model in which RNAs containing
expanded CUG/CCUG forms stable hairpin structures which alters the
activities of various RNA binding proteins like CUGBP1/ETR3-like factors
(CELF) and MBNL proteins. The RNAs containing the expanded repeats
accumulates in the nucleus where they sequester all three MBNL proteins
(MBNL1, MBNL2 and MBNL3). MBNL1 plays an important role in
regulating alternative splicing in skeletal and cardiac muscle (O'Rourke and
Swanson, 2009). Thus, its depletion from the nuclear pool results in
misregulated alternative splicing of many other transcripts. In my thesis I have
focussed mainly on the sub-cellular distribution of MBNL1 protein and its role
in DM. The main aims of my research were:
1. To compare different separation methods to study the sub-cellular
(Nuclear v/s Cytosolic) distribution of Muscleblind-like protein 1 in
Normal and DM cells. I have compared two separation techniques, the
first one involves use of Nonidet P-40 buffer and the second one
involves use of physical shearing method using a syringe to separate
nuclear and cytoplasmic fractions.
2. To assess the effect of compounds that came up as positive hits in
primary screening on MBNL1 nucleo-cytosolic distribution in DM1
fibroblasts and myoblasts. I have used western blot analysis to
determine this.
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3. To determine the effect of compounds (positive hits) on the MBNL1
protein in the foci (MBNL foci) using immunocytochemistry studies.
4. To assess the effect of MBNL1 and 2 down regulation on the nuclear
foci in DM1 cells.
5. To assess the effect of Antisense oligonucleotides (AONs) on MBNL1
protein sub-cellular distribution in DM myoblasts
6. To determine the phosphorylation state of MBNL1 protein and to map
the phosphorylated site (s) using Mass Spectrometry and IP.
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Chapter -2: Methods and Materials
2.1 Cell culture
Tissue cell culture was carried out inside a laminar flow cabinet in tissue
culture room.
2.1.1 Cell lines
Cell lines used in the study include human fibroblasts cell lines from DM1
(KB-Telo MyoD) and DM2 (KAGO-Telo) patients. Two wild type lines were
also used NIRA-Telo and SB-Telo MyoD; contains an inducible MyoD gene,
which is expressed in the presence of doxycyclin promoting the differentiation
of fibroblast cells into myoblasts cells. All the cells used in the study had been
previously telomerised that is they express telomerase so they were able to
grow continuously in culture over extended period of time. DM myoblasts and
control myoblast cells were also used in our study. CTG repeat sizes were;
KBTeloMyoD - 400 repeats and DM15  3000 repeats.
2.1.2 Media and solutions
Medium used in the study was Dulbeccos minimum essential media (DMEM)
from Gibco life technologies containing 4500 mg/L glucose, L-glutamine and
pyruvate. Other solutions used in tissue culture were Foetal bovine serum
(FBS) from Gibco life technologies, Antibiotics Penicillin and Streptomycin
from Gibco, Phosphate buffer saline (PBS), 0.25% Trypsin-EDTA solution
from Sigma and Dimethyl Sulphoxide (DMSO) from Sigma.
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2.1.3 Media for fibroblasts and myoblasts
Dulbeccos Modified Eagles Medium (DMEM) with penicillin (10,000 units of
Penicillin G) and streptomycin (10,000 µg/ml), and 10% fetal calf serum (FBS)
was used to grow fibroblast cells. In the case of myoblasts, the cells were first
grown in Hams F10 containing penicillin and streptomycin with 20% FBS and
then differentiated for 5-6 days into myotubes in DMEM containing low serum
(1% FBS) to stop them from proliferating.
2.1.4 Passaging of cells
For fibroblast and myoblast cell lines, cells were sub-cultured after reaching
80%-100% confluency, which was determined by visualizing the cells under
the microscope. Firstly, the media was decanted and the cells were mildly
rinsed with 10 ml pre-warmed PBS followed by addition of 2 ml of 0.25%
Trypsin-EDTA to the flask containing the cells. The cells were then incubated
in the 37°C and 5% CO2 incubator for 2 min in order to remove the cells from
the base of the flask. The cells were visualized under microscope to confirm
dissociation and 11 ml of new medium was added to the flask and gently
pipetted up and down to dissolve the cells homogenously. The cells were then
split into new sterile 75 cm
3
flasks depending on the required cell concentration
which was usually 1/3 in our studies.
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2.1.5 Cryopreservation and Storage of Cells
DMSO was used as a cryopreservant for human fibroblasts and myoblasts. For
freezing the cells, medium was decanted and cells were washed with 10 ml of
pre-warmed PBS. Cells were then trypsinized with 2 ml of 0.25% trypsin
EDTA to dissociate them from the bottom of flask by incubating the flask at
37°C incubator. Following trypsinization the cells were resuspended in 10 ml
of fresh media and pelleted by centrifugation at 2000 rpm for 3 minutes.
Supernatant was discarded and the cells were resuspended in 1 ml of fresh
media containing 10% (v/v) DMSO. The cells were then instantly transferred
to cryotubes for storage at -80°C for 24 hours and finally transferred to liquid
nitrogen for storage.
2.1.6 Defrosting and reviving cells from liquid nitrogen
Cryovials containing the frozen cells were removed from liquid nitrogen and
immediately placed into a 37°C water bath. The cells were quickly thawed (<1
minute) by gently swirling the cryovial in the water bath. The vial was
immediately transferred into the laminar hood. 1 ml of pre-warmed complete
media was added dropwise to the vial containing the thawed cells. The solution
was then again transferred to a universal tube containing 9 ml of complete
media. The cell suspension was then centrifuged at approximately 1000 rpm
for 1-2 minutes. After the centrifugation the supernatant was decanted
aseptically without disturbing the cell pellet. The cell pellet was then gently
resuspended with 20 ml of new complete media and transferred into a T-75
flask and incubated overnight in 37°C incubator.
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2.1.7 Transfection of Cells
Human fibroblasts cells were transfected with plasmid DNA or siRNA using
the Amaxa Transfection system, according to the manufacturers instructions.
siRNAs oligonucleotides used for MBNL1 and MBN2 down-regulation were
ordered from Invitrogen, UK. The sequences of siRNAs used in my study
ZHUHIRU0%1/ƍ&$&8**$$*8$8*8$*$*$G7G7ƍIRU0%1/
HTXLPRODUDPRXQWVRIWZRVL51$Vƍ&$&&*8$$&&*888*8$8*G7G7
ƍ DQG ƍ *$**$$&$8*&8&$&*&8&G7G7ƍ ZHUH XVHG DQG IRU
VFUDPEOHG VL51$ ƍ*&*&*&888*8$**$88&*G7G7 ZDV XVHG
(Dansithong et al., 2005).
2.2 Immunocytochemistry
2.2.1 Seeding of cells into 96-well plate
The cells were seeded into 96-well plates and allowed to grow for 24 hours to
attain 80% confluency. After 24 hours incubation, the cells were ready for
compound treatments (48 hours exposure) followed by either
Immunofluorescence or RNA Fluorescence in situ Hybridisation (RNA-FISH).
2.2.2 Fixation
Media was taken off 96-well plates and cells were washed thrice with PBS.
Fixation of the cells was performed using ice cold methanol: acetone (1:1) for
30 minutes at room temperature. The wells were again washed three times (5
mins each wash) with PBS before blocking step.
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2.2.3 Blocking
The cells were blocked with 3% BSA + 5% goat serum in PBS for 1 hour at
room temperature to decrease the non specific interactions.
2.2.4 Antibody staining
After blocking, the cells were washed thrice with PBS (5 mins each wash) and
incubated with 1% BSA containing diluted primary MBNL1 antibody (1:2000)
for overnight at 4°C. Next day the cells were then rinsed thrice with PBS and
incubated at room temperature with 1% BSA containing diluted secondary
antibody (1:500), Alexa 647 goat anti-mouse IgG. The cells were washed with
PBS thrice and incubated again with Hoechst dye for 10 mins to stain the
nuclei. The Hoechst was then replaced with PBS and stored at 4°C for future
scanning on the plate reader.
2.3 RNA Fluorescence in situ Hybridisation (RNA-FISH)
RNA-FISH was performed on wild type, DM1 fibroblasts and DM myoblasts
cells to visualize bright spots/foci which contained RNA transcripts with
expanded CUG repeats. Cells were exposed to compounds for 48 hours after
which in situ hybridisation was performed to identify foci using Cy5 labelled
(CAG)10 probe for DM1. Cells were first washed with PBS thrice followed by
fixation with 4 % PFA for 30 mins at room temperature. After fixation, the
cells were again washed thrice with PBS to get rid of any excess of PFA. To
permeabilise the cells, 80% ethanol was used for 15 mins at room temperature
followed by three washes with PBS. The cells were then treated with
prehybridisation (Prehyb) mixture for 15 mins which contained formamide and
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20 x SSC in DEPC water. After treatment with Prehyb solution, the cells were
treated with hybridisation (Hyb) solution containing Formamide, 20x SSC,
BSA, salmon sperm DNA, Vanadyl Adenosine complex (VAC) and Cy5
labelled oligonucleotides probe. The exact recipe for Prehyb and Hyb used is
described in table 2.1. The cells were then incubated overnight at 37°C in a
moist chamber. Next day the cells were washed with thrice with 5mM MgCl2
in PBS. This was followed by Hoescht staining for 10-15 mins and stored at
4°C for future scanning at plate reader. Plates were analysed on a Molecular
Devices Micro High Content Imaging system. Number of cells imaged in a
single well was approximately ~100.
Recipe for 10 ml
Prehyb solution Hyb solution
4 ml Formamide 4 ml
1 ml 20 X SSC 1 ml
5 ml DEPC H20 5 ml
- BSA 20 µl
- ssDNA 100 µl
- VAC 10 µl
x Probe (Cy5 or Cy3) -1 µl per every 2ml Hyb. Solution used.
Table 2.1 Recipe for Prehyb and Hyb solution used in in situ experiments
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2.4 Compound treatment of DM cells
384 well plates were used to screen each compound in triplicate. Each well
contained approximately 1.6 x 10
4
cells. For Chembrige Diverset library,
compounds were tested at concentration of 40 µM. For the NPC library,
FRPSRXQGV ZHUH WHVWHG DW WKUHH GLIIHUHQW FRQFHQWUDWLRQV ȝ0 ȝ0 DQG
ȝ0LQZHOOIRUPDW7KHNLQDVHDQGSKRVSKDWDVHOLEUDULHVZHUHVFUHHQHG
LQZHOO IRUPDWZLWKFRPSRXQGFRQFHQWUDWLRQVRIȝ0ȝ0ȝ0DQG
100nM. All the secondary validation screens were done over a 12 point
GLOXWLRQ UDQJH IROORZLQJDGLOXWLRQSURWRFRO UDQJLQJ IURPȝ0WR
pM in 96-well format.
In case of western blotting experiments showing the effect of compounds on
MBNL1 distribution before and after the treatment, the cells in 75cm
3
flasks
were first grown to a confluency of 80-90% cell density. The media was then
removed and replaced with the new media containing compounds and the cells
were then exposed further for 2 days before extracting sub-cellular proteins
from them. The compounds were used at different concentrations, such as RO
31-8220 (10µM), hypericin (10µM), gemcitabine (10µM), chromomycin A3
(40nM), and IMOX (10µM).
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2.5 Immunoprecipitation
2.5.1 Cell lysis
Cells were grown in T75 tissue culture flask for 3 days. Total cell extract was
obtained as described in section 2.6.1. The cell pellet obtained was treated
with 1ml of RIPA buffer for complete lysis before conducting the
immunoprecipitation experiments with serine, tyrosine and threonine phospho-
specific antibodies.
2.5.2 Preparation of Dynabeads Protein G
Dynabeads were completely resuspended by pipetting up and down or by
rotating on a roller for 2 mins. 50µl of Dynabeads were transferred to a new
eppendorf and separated on a magnet until the supernatant was clear and then
removed.
2.5.3 Binding of Antibody
10µl of MBNL1 (MB1a) antibody was added to a fresh tube containing 200µl
of Ab binding and Washing buffer (already supplied with the kit, # 100.07D,
Invitrogen, UK). The whole mixture was then incubated with rotation for 10
mins at room temperature. The tube was then placed on the magnet and
supernatant was removed. The beads were washed again by resuspending in
200 µl Ab binding and washing buffer before removing the supernatant and
proceeding to immunoprecipitation.
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2.5.4 Immunoprecipitation of Target Antigen
Sample (total cell extract) containing the antigen (Ag) (typically 1000 µl) was
added to the tube containing the beads and antibody and gently pipetted to
resuspend the Dynabeads-Ab complex. The whole mixture was incubated at
4°C for overnight. Next day, the supernatant was removed by placing the tube
on magnet and the Dynabeads-Ab-Ag complex washed three times using 200
µl washing buffer (included in the kit) for each wash.
2.5.5 Elution of Target Antigen
After the washing steps, the tube was placed on magnet and supernatant
removed. 20µl of elution buffer and 10 µl of premixed NuPAGE LDS sample
buffer were added to the Dynabeads-Ab-Ag complex. NuPAGE sample
reducing buffer was also added to the tube (as per manufacturers instructions).
The whole mixture was heated for 10 min at 70 °C before loading the
supernatant onto a western gel. After completing the western blot, the
membrane was probed with phospho-specific antibodies to investigate if
MBNL1 protein was phosphorylated and at which residue.
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2.6 Protein Analysis
2.6.1 Preparation of total cell protein from Fibroblast and Myoblast cells
The cells were grown in a T75 flask, 75 cm
2
tissue culture flasks. The media
was decanted and the cells rinsed once with 10 ml of pre-warmed PBS. 2ml of
trypsin was added to the flask and incubated for 3 min until the cells detached
from the base of the flask and started rounding up. 1 ml of trypsin was
discarded and the flask was gently shaken to detach the cells from bottom of
the flask. 9 ml of fresh media was added to neutralize trypsin and pipetted up
and down. The entire volume was transferred into a universal tube and
centrifuged for 3 mins at 2000 rpm. The supernatant was discarded and the
pellet was resuspended with 10 ml of PBS to remove any residual media.
Whole volume was centrifuged for 3 mins at 2000 rpm. The supernatant was
again discarded and pellet was stored in -80°C for subsequent use. The pellet
was then treated with RIPA buffer for complete lysis followed by 2 cycles of
freeze-thaw before loading it on western blotting.
The recipe for RIPA buffer used:
x Tris 50mM, pH 8.0
x NaCl 150 mM
x SDS 0.1%
x Deoxycholic acid 0.5%
x Nonidet P40 1%
x Protease inhibitors such as PMSF or protease inhibitors cocktail
which are commercially available.
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2.6.2 Subcellular fractionation using buffers (Nuclear and cytosolic
fractions)
Subcellular fractionation was carried out to separate nuclear and cytosolic
proteins. Cultured DM1, DM2 and control cells were separated into subcellular
fractions using Nonidet P-40 solution (0.65% Nonidet P-40, 0.01 M Tris-HCL,
pH- 7.9, 0.15 M NaCl and 1.5 mM MgCl2 in Sterile Distilled Water). This
concentration of detergent was able to break the cytoplasmic membrane but
was not powerful enough to break the nuclear membrane. So it was used to
obtain the cytoplasmic contents of a cell. Media was decanted from the flask
containing the cells. The cells were then washed once with 10 ml of cold PBS.
1 ml of Nonidet P-40 solution was added to the flask and incubated for 2 mins
at room temperature. Without disturbing the cells, the entire 1 ml volume was
pipetted out in an eppendorf as cytosolic fraction. 5 ml of Nonidet P-40
solution was added to the flask and transferred to a universal tube followed by
centrifugation at 2000 rpm for 5 mins. Supernatant was discarded and the
visible pellet was resuspended in 200 µl of RIPA buffer to obtain the nuclear
fraction.
2.6.3 Subcellular fractionation using the physical shearing method
The subcellular distribution of MBNL1 can vary with the culture conditions.
The subcellular distribution of MBNL proteins may be responding to local
signals or culture conditions, rather than any internal myogenic program. So I
decided to use physical shearing method using a syringe. The cells were
grown in T75 tissue culture flask. Media was decanted and the cells were
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washed with PBS. 500µl of ice cold PBS (+ PMSF or protease inhibitors
cocktail) was added to the flask. The cells were then scraped off the bottom of
the flask using a cell scraper and the lysate collected in a 1.5 eppendorf tube.
20 Gauge needle with a 5 ml syringe was assembled. The lysate was carefully
passed through the needle 12-15 times to disrupt the cytoplasmic membrane of
the cells. Care was taken not to use the same needle for a different cell line or
compound treatment. The suspension was then centrifuged at 13000 rpm at
4°C to collect the supernatant (as cytosolic fraction) and the pellet was
resuspended in 500 µl of RIPA buffer to obtain the nuclear fraction. Two free-
thaw cycles were performed on nuclear extract to completely break the nuclear
membrane before loading both the samples on western blots.
2.6.4 Quantification of Protein
Protein was quantified using the BioRad DC protein Assay. The DC
TM
(detergent compatible) protein assay is a colorimetric assay for protein
concentration following detergent solubilisation. It is based on the Lowry assay
but modified to save time. A standard BSA curve was plotted with known
concentration of BSA ranging from 10µg/ml to 70µg/ml in RIPA buffer or any
other buffer used while extracting cytosolic or nuclear fractions and the
concentrations of protein in the samples were extrapolated using the standard
curve.
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2.6.5 Western Blot
A commercial NuPage system from Invitrogen, UK was used to perform
western blotting according to the instructions provided in their manual.
Sample preparation
Protein samples were mixed with LDS sample buffer and with reducing agent.
The protein samples containing the LDS were then heated at 70 °C for 15 mins.
The total reaction volume was not exceeded over 17µl due to holding capacity
of the wells in the pre-cast Invitrogen gels.
SDS-PAGE
Before running the SDS-PAGE, running buffer was prepared by mixing 40 ml
of MOPS buffer (10X) with 760 ml of sterile distilled water to make a final
volume of 800 ml. Pre- cast 10% bis-Tris gels from Invitrogen, UK were used
for western blotting. Before loading the samples on the gel, the comb was
carefully removed without disrupting the wells. The gels were then rinsed in
running buffer thrice before arranging it in X-cell Surelock mini-cell system.
The chamber was put in right position and the clamp was carefully closed. The
chamber was filled with SDS running buffer till the top. The samples were then
loaded (10µl- 15µl) into the wells. Pre-stained marker (acts as a control for
visualization during protein transfer step) and Magicmarker were loaded in the
first two wells. SDS-PAGE was performed using a NuPAGE gel program
which was set for 50 min to run at a constant voltage of 200 V.
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Transferring proteins to PVDF membrane after SDS-PAGE
40 ml of transfer buffer (10 X) was mixed with 80 ml of methanol in 680 ml of
SDW (Sterile Distilled Water) to prepare transfer buffer. Four bloating pads
were immersed completely into transfer buffer until they reached saturation.
Any visible air bubbles were removed carefully by tapping on them. Removing
the air bubbles is important as they can obstruct the transfer of proteins from
gels to PVDF membrane. PVDF membrane was soaked in methanol for 30
seconds before the transfer which was followed by wash with sterile distilled
water and then placed in a container containing 200 ml of transfer buffer to
equilibrate. After gel electrophoresis was completed, the gel cassettes two
plates were separated by inserting the gel knife. Finally the gel membrane
sandwich was set according to the instructions in the Invitrogen, NuPAGE
manual. The entire sandwich was placed in the inner chamber which was then
filled with transfer buffer. Care was taken to fill the outer chamber with sterile
distilled water. The proteins were then transferred for 1 hour at 30 V.
Detection
Post transfer step, the membrane was rinsed thrice in dH20 for 10 min each
followed by blocking step in 20 ml of TBS-T (TBS-Tween buffer) containing
5% blotto (dry milk powder, Invitrogen, UK) or BSA for overnight at 4°C on a
shaker. The following day, the membrane was rinsed again with TBS-T buffer
twice (10 min each) and incubated with 10 ml of primary antibody solution
containing 3% BSA for 4 hours at room temperature on shaker. After
incubation with primary antibody the membrane was rinsed thrice (10 min
each) with TBS-T buffer followed by incubation with 10 ml of TBS-T buffer
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containing 3 % BSA and secondary antibody (Anti-rabbit IgG or anti-mouse
IgG). The membrane was then rinsed thrice with TBS-T buffer (10 min each)
to wash off any residual secondary antibody. The membrane was then finally
placed on a cling film and incubated with detection reagent (ECL plus) for 5
minutes. The membrane was then dried with filter paper to drain any excess
ECL solution. In the end the membrane was placed in a photographic cassette
and exposed to X-ray film.
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Name of
antibody
Antigen/Isotype Details Dilution
MB1a (a kind gift
from Dr. Ian Holt
(Holt et al.,
2009))
Human MBNL1
protein
Mouse
monoclonal
culture
supernatant
1:5000
ĮWXEXOLQ
(Santa Cruz)
+XPDQĮWXEXOLQ 0RXVH
monoclonal
concentration-
200µg/ml
1:500
Lamin-B
(Santa Cruz)
Human Lamin B Mouse
monoclonal
culture
supernatant
1:500
MB1a 4A8
IgG1
Mouse
monoclonal
culture
supernatant
1:5000
MB2a 3B4
IgG2b
Mouse
monoclonal
culture
supernatant
1:100
Phospho-serine
(Acris Antibodies)
IgM Monoclonal 1:100
p-Tyr Antibody
(Santa Cruz)
IgG2b Monoclonal 1:100
p-Thr (H-2)
(Santa Cruz)
IgG1 Monoclonal 1:100
Table 2.2 Details of primary antibodies used in western blot.
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2.7 RNA Analysis
2.7.1 Total RNA extraction
Cells were grown in T75 tissue culture flasks before they were trypsinized and
pelleted at 2000 rpm for 5 mins. Supernatant was discarded and the pellet was
resuspended in 1 ml of TRI-Reagent (# AM9738, Applied Biosystems). TRI
Reagent solution combines phenol and guanidine thiocyanate in a monophasic
solution to quickly inhibit RNase activity. Addition of bromochloropropane
(BCP) leads to the separation of homogenate into aqueous phase (containing
RNA), interphase (containing DNA) and organic phase (containing proteins).
After resuspending the pellet in TRI Reagent, the tube was incubated for 5
mins at room temperature before adding 100µl of BCP. Followed by
incubation for 15 mins at room temperature, it was subsequently centrifuged
for 12000 g for 10-15 mins at 4 °C. The aqueous phase was then collected in a
fresh tube and 600 µl of isopropanol was added and vortexed immediately at
moderate speed. After incubating the tube for 5-10 mins at R/T, it was
centrifuged again for 12000 g for 8 mins at 4 °C. Supernatant was discarded
and 1 ml of 75 % ethanol was added to wash the pellet. The pellet was air dried
for 3-5 mins before dissolving the pellet with 100 µl of DEPC water. The
amount of RNA was quantified on the nanodrop and used for subsequent
reverse transcription experiments. The remainder was stored in -80°C for
future use.
65
2.7.2 Fractionated RNA Extraction
RNAse-free pipettes and tips were used for extracting Nuclear and
Cytoplasmic RNA fractions from cell culture. Cells grown in T75 Tissue
culture flask were washed once with 10 ml of cold PBS.1 ml of solution 1
(Nonidet P40, 0.65%; 0.01M Tris HCl, pH 8.0; 0.15M NaCl and 1.5mM
MgCl2 in DEPC H2O) was then added to cover the cells (to break cell wall).
Cells were incubated for 1 min at room temperature, before transferring the
entire volume into a fresh tube labelled with cytoplasmic fraction. 2ml of
solution 1 was again added to the flask, with gentle tap on the side of flask to
collect everything into a fresh tube (Nuclear fraction). Tubes were placed on
ice throughout. Both the tubes were then centrifuged for 5 mins at top speed at
4°C. 800 µl of cytoplasmic fraction was pipetted out and was mixed with 200
µl of solution 2 (10% SDS, 0.05M EDTA and 0.5M Tris/HCl pH 8.0) in a fresh
tube. In case of nuclear fraction, supernatant was discarded and pellet was
resuspended in 400 µl DEPC H20 and 100 µl of solution 2.
In Fume Hood
Tubes were then transferred to the fume hood. 500 µl chloroform and 500 µl
phenol were added to the tube containing cytoplasmic fraction. In case of
nuclear fraction, 250 µl of chloroform and 250 µl phenol were added. The
tubes were then vortexed at top speed for 5 min at 4°C. The aqueous layer from
both the tubes was then transferred into 2 fresh tubes. Centrifugation step was
repeated 2 times. The tubes were again centrifuged for 30 min and supernatants
discarded.
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Out of Fume Hood
To the cytoplasmic fraction, 1 ml of isopropanol and 200 µl of 3M NaOAc
were added. 0.5 ml isopropanol and 100 µl of 3M NaOAc were added to the
nuclear fraction, followed by centrifugation at top speed for 30 min at 4°C. The
supernatants were then discarded from both the tubes and the pellets were
washed with 75 % ethanol. In the end the pellets were air dried and dissolved
in 25 µl of DEPC H20, prior to RNA quantification on nanodrop.
2.7.3 DNase Treatment
Total RNA and cytoplasmic RNA samples were treated with DNase1 to
remove contaminating DNA from RNA preparations. 1µl of 10x RNase-free
DNase buffer (New England BioLab protocols) (400mM Tris-HCl/pH-8.0, 100
mM MgSO4 and 10 mM CaCl2) and 1µl of enzyme RNase-free DNase (1U/µl
for every 1 µg of RNA used) was added to RNA samples and incubated at
37°C for 30 min. After incubation 1µl of DNase stop solution was added to the
mixture and again incubated at 65°C for 10 min to inactivate the DNase1
enzyme prior to using for reverse transcription reaction.
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2.8 Molecular Biology Techniques
2.8.1 Reverse Transcription PCR
After treatment with DNase1, the RNA sample (1-2 µg preferably) was added
to a fresh eppendorf tube containing 4 µl of 1mM dNTPs, 4 µl of Random
hexamors with DEPC H20 to give a final volume of 16µl. The mixture was
then incubated for 5 mins at 70 °C, centrifuged and put on ice immediately. 2µl
of 10X reverse transcriptase buffer (NEB) (500nM Tris-HCl, 750mM KCl,
30mM MgCl2 and 100nM dithiothreitol), 1µl of RNase inhibitor (New England
BioLabs,UK) and 1 µl of 200 Units/µl reverse transcriptase enzyme were
added to the tube. The mixture was then incubated at 42°C in water bath for 90
mins followed by incubation at 90°C to inactivate the enzyme before PCR.
For BpmI analysis of DMPK, 1/20
th
of the synthesized cDNA was used for
PCR amplification with MegaMix (Microzone) using N11 as forward primer
(5´- CACTGTCGGACATTCGGGAAGGTGC) with 133 as reverse primer
(5´- GCTTGCACGTGTGTGGCTCAAGCAGCTG). Amplification was done
with a Tm of 58°C, by modifying the protocols used by Hamshere et al (1997).
The PCR product was then heated to 95 °C for 2 minutes followed by cooling
to 4°C. For BpmI restriction digestion analysis of DMPK PCR products, 4µl of
the PCR mixture was digested overnight with restriction enzyme BpmI (New
England BioLabs, UK) in a total reaction mixture of 20 µl at 37°C followed by
incubation for 10 minutes at 65°C. The final products were then analysed by
electrophoresis at 80-90V using a 3% agarose gel. Finally the density of bands
quantified using ImageJ software.
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2.8.2 Gel Electrophoresis
Gel electrophoresis was used to separate and analyze DNA and their fragments,
based on their size and charge. Depending on the size, the DNA fragments
were analysed on 1-3% (w/v) gels. For DNA of 1Kbp and above, a standard
1% gel was prepared by dissolving 0.4 gms of agarose in 40 ml of 1X TAE
buffer (40 mM Tris-HCl, 50 mM EDTA/pH-8.0, 0.1% (w/v) glacial acetic
acid) in the microwave oven and then cooled. 3% agarose gel was used to
separate DNA sizes of less than <300 bp. 10µl ethidium bromide, most
common dye to visualize DNA or RNA bands was added. Before loading the
DNA samples, loading buffer (30% glycerol, 0.025% bromophenol blue and
0.025% xylene cyanol) was added to each sample (final concentration 1X).
Finally DNA samples and marker (1Kb ladder) were loaded and gels
electrophoresed at 60-90V for 1-1.5 hour in 1X TAE buffer. DNA fragments
were visualized under ultra-violet (UV) irradiation using BioRad GelDoc
system.
2.9 Microscopy
2.9.1 Brightfield Microscopy
Cell imaging in tissue culture was performed using a brightfield microscope
fitted with 4x, 10x and 40x objectives.
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2.9.2 High Throughput Imaging
Cells were visualized on Molecular Devices ImageXpress Micro widefield
high content plate reader fitted with Nikon 40x ELWD. Cells after
immunofluorescence and RNA-FISH analysis were imaged using this machine.
2.10 Electronic Databases
National Centre for Biotechnology Information (NCBI) and Ensembl were
used to access information about transcripts and nucleotide and protein
sequences. Primers were designed using a web version 4.0 of primer3 Input.
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Chapter- 3: Results
Distribution of Muscleblind-like proteins in normal
and DM cells.
3.1 Introduction
Expanded CTG and CCTG repeats expression is proposed to have a trans-
dominant effect, which alters the activity of RNA-binding proteins like
Muscleblind-like (MBNL) proteins. These proteins play an important role in
mediating pre-mRNA alternative splicing regulation. Besides its nuclear role,
0%1/ZDVIRXQGWRKDYHDUROHLQORFDOLVDWLRQRILQWHJULQĮ51$WRIRFDO
adhesion complexes in cytoplasm. MBNL2 was reported to bind to an
ACACCC motif in the 3´ UTR of integrin alpha 3 mRNA to transport it to the
adhesion complexes. It has been shown that all Muscleblind-like proteins have
similar structures, thus it is quite possible that they may have similar functions
also (Pascual et al., 2006). As already shown by Saloni Mittal (2008), MBNL1
is not confined to the nucleus but shuttles between the nucleus and the
cytoplasm. The ability of MBNL1 to shuttle between the nucleus and
cytoplasm implies that in addition to its role in regulating alternative splicing,
it may also be involved in mRNA transport across the nuclear envelope, have
cytoplasmic functions such as translational regulation, and affect mRNA
stability or mRNA localization. In this section I have attempted to assess the
sub-cellular (Nuclear v/s Cytosolic) distribution of Muscleblind-like proteins in
Normal and DM cells. Holt and colleagues (2009) showed that different
fixation methods can affect the visualization of MBNL1 in the nucleus
compartment. They used acetone: methanol fixation method which allowed
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partial loss of soluble MBNL proteins from both cytoplasm and nucleoplasm
for reliable visualization of nuclear foci without high nucleoplasmic MBNL
staining (Figure 3.1). Thus, In view of these findings, I decided to compare
different separation methods to study the sub-cellular (Nuclear v/s Cytosolic)
distribution of Muscleblind-like protein 1 in Normal and DM cells.
Figure 3.1 Comparison of acetone: methanol and formalin fixation
methods. (A) Cultured human DM1 myoblasts (800 CTG) fixed and
permeabilized with acetone: methanol showing clear foci without high
nucleoplasmic MBNL staining (B) or with formalin followed by Triton X-100
which resulted in quite high nucleoplasmic MBNL1 staining, which can
obscure the foci (Images taken from Holt et al., 2009) (Holt et al., 2009) .
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3.2 Comparison of different sub-cellular separation methods
In this section I have compared different separation methods to study the sub-
cellular (Nuclear v/s Cytosolic) distribution of Muscleblind-like protein 1 in
normal and DM cells. In section 3.2.1, I have used Nonidet P-40 buffer to
extract nuclear and cytosolic fractions whereas in section 3.2.3, I have used
physical shearing method to extract nuclear and cytosolic protein fractions.
3.2.1 Separation into two compartments i.e. Nuclear and Cytosolic
fractions using Nonidet P-40 buffer
To give a clear indication of MBNL1 distribution in individual sub-cellular
compartments, it was important to perform western blotting with representative
loading rather than equal loading. As the nucleus forms a small part of the
entire cell and majority of space is cytosolic, therefore it would be misleading
to load (in western blotting) equal amounts of proteins for both nuclear and
cytosolic fractions. Thus, a detailed representative loading for each
compartment was performed. Nuclear and cytosolic fractions were extracted
separately from 2 x 10
6
cells and re-suspended each of them in equivalent
volumes (Table 3.1). The total amount of protein in each fraction was
measured and an equivalent volume loaded on to a gel. Typically this would be
one hundredth of the total, equivalent to 2 x 10
4
nuclei and similar numbers of
cytoplasms. For example 3µl of total cell extract (1/100
th
of the total volume
in the tube), 2µl of nuclear extract (1/100
th
) and 10µl of cytosolic extract
(1/100
th
) was loaded on gels because they all were extracted in different
volumes of buffers (either RIPA or Nonidet P-40) during their preparation as
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described in Table 3.1. Thus, the protein loaded on gels is from an equivalent
number of nuclei and cytoplasms for each cell line. It is therefore
representative of the distribution of all cellular proteins.
Cultured DM1, DM2 and control fibroblasts were extracted with Nonidet P-40
solution, to prepare nuclear and cytosolic fractions for western blotting. Lamin
B and Tubulin were used as controls to determine the extent of cross-
contamination of nuclear and cytosolic compartments during extraction.
Initial analysis revealed that both the DM and control cells show a greater
proportion of MBNL1 protein in the cytosolic fraction than in nuclear fraction
(Fig. 3.2). In both DM1 and DM2 cells the amount of cytosolic MBNL1 was
97% and 96 % respectively and proportion of the nuclear MBNL1 was much
less (3-4%). The same pattern was observed in control (NIRA) cells, where
98% of MBNL1 was present in cytosolic fraction with much less (2%) present
in nuclear fraction (Fig.3.4).
Analysis for MBNL2 distribution also showed a greater proportion of MBNL2
in the cytosolic fraction than in nuclear fraction for both DM and non-DM
fibroblast cells (Fig. 3.3). Histograms compiled from intensity scans of
triplicate samples suggested that majority of MBNL is cytosolic (free MBNL)
with much less present in nuclear compartment for both DM and non-DM cells
(Fig.3.5).
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Type of extract Resuspension volume Volume loaded on W.B
Total cell extract
(Normal and DM cells)
300 µl (RIPA buffer) 3 µl (equivalent of ~2 x
10
6
cells)
Nuclear extract
(Normal and DM cells)
200 µl (RIPA buffer) 2 µl (equivalent of 2 x
10
4
nuclei)
Cytosolic extract
(Normal and DM cells)
1000 µl/ 1ml
(Nonidet P-40)
10 µl (equivalent of 2 x
10
4
cytoplasms)
Table 3.1 Volumes used for representative loading during western
blotting.
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Figure 3.2 Sub-cellular distribution of MBNL1. (A) Distribution of MBNL1
in NIRA-TELO (Normal), KAGO-TELO (DM2) and KB-TELO MYOD
(DM1) cell lines (B) &RQWURO Į WXEXOLQ DW a N'D F\WRVROLF SURWHLQ (C)
Control Lamin- B (nuclear protein).
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Figure 3.3 Sub-cellular distribution of MBNL2. (A) Distribution of MBNL2
(MB2a) in NIRA-TELO (Normal), KAGO-TELO (DM2) and KB-TELO
MYOD (DM1) cell lines (B) &RQWUROĮWXEXOLQ(C) Control Lamin-B.
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B C
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Figure 3.4 The sub-cellular distribution of MBNL1. Histograms show data
compiled for MBNL1 sub-cellular distribution in NIRA-Telo (Normal),
KAGO-Telo (DM2 cell line), and KB-Telo MyoD (DM1 cell line) from
intensity scan of blot in Fig. 3.2 (A), normalized against values for lamin-B and
tubulin.
Figure 3.5 The sub-cellular distribution of MBNL2. Histograms show data
compiled for MBNL2 sub-cellular distribution in NIRA-Telo (Normal),
KAGO-Telo (DM2 cell line), and KB-Telo MyoD (DM1 cell line) from
intensity scan of blot in Fig. 3.3 (A), normalized against values for lamin-B and
tubulin.
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3.2.2 Separation into two compartments i.e. nuclear and cytosolic fractions
using Nonidet P-40 (Ice cold conditions)
The fractionation using buffer Nonidet P-40 worked quickly and I watched
through an inverted microscope as the lysis took place on the cell monolayer.
In general this whole procedure took 2-3 min. However, I decided to repeat the
extraction on ice to test whether the MBNL1 protein distribution was an
artifact of the procedure. The sub-cellular fractionation was performed again to
separate nuclear and cytosolic proteins at 4ºC on ice. Cultured DM1, DM2 and
control fibroblasts were extracted with Nonidet P-40 solution as before. The
cultured DM1 and DM2 fibroblasts were kept on ice throughout the separation
protocol. Care was taken to use ice cold buffers every time. Figure 3.6 shows
the subcellular distribution of MBNL1 in KAGO Telo (DM2) and in KB-Telo
MyoD (DM1) cell line, nuclear and cytosolic fractions prepared under ice cold
conditions. Again representative loading was followed as indicated in Table
3.1. Consistent with previous experiments, MBNL1 appeared to predominate in
the cytosolic fractions with much less in the nuclear fractions (Fig.3.6A).
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Figure 3.6 Effect of ice cold conditions on subcellular distribution of
MBNL1 protein. (A) Subcellular distribution of MBNL1 in KAGO-TELO
(DM2) and in KB-TELO MYOD (DM1) cell line (B)&RQWUROĮWXEXOLQa
kDa) (C) Control Lamin-B. MBNL1 protein was still found to be predominant
in cytosolic fractions than in nuclear fractions.
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3.2.3 Separation into two compartments i.e. Nuclear and Cytosolic
fractions using physical separation method
In the previous experiments, endogenous MBNL1 and MBNL2 were found to
be predominantly cytosolic in normal and DM cell lines. In order to test
whether the subcellular distribution of MBNL1 can vary with the culture
conditions, I decided to use physical shearing method using a syringe instead
of the buffers/detergents. Representative loading was followed for western
blots as described in Table 3.2. To calculate the percentage of nuclear MBNL1,
I extracted nuclear and cytoplasmic protein fractions separately from 2 x 10
6
cells and re-suspended each of them in equivalent volumes. The total amount
of protein in each fraction was measured and an equivalent volume loaded on
to a gel. Typically this would be one fiftieth of the total, equivalent to 4 x 10
4
nuclei and similar numbers of cytoplasms. Following western blotting the
proteins were detected with MBNL1 antibody (MB1a), a mouse monoclonal
antibody against MBNL1 (generated by Dr. Ian Holt). The validity of this
antibody in normal and DM fibroblasts has already been tested by Dr. Ian Holt
(Holt et al., 2009). MB1a antibody recognises a band corresponding to
molecular weight of 41~42 kDa on western blots. MBNL1 protein consists of
several isoforms of similar size and in protein extracted from our cell lines.
Therefore, MBNL1 always appeared as a double band in all our blots. The
relative intensity of nuclear and cytosolic bands was estimated using Image J
software. The values were normalised by comparison to lamin (for nuclear) and
alpha tubulin (for cytoplasmic) to indicate the extent of cross contamination
(usually less than 3%), and expressed as the percentage of nuclear MBNL1
relative to the cytoplasmic.
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The histogram data compiled from the intensity scans of triplicate samples
show that the percentage of nuclear MBNL1 was 16.45% in NIRA-Telo (non-
DM) fibroblast cells (Fig. 3.7). But in case of sub-cellular distribution of
MBNL1 in KAGO-Telo (DM2 cell line) and KB-Telo MyoD (DM1 cell line)
the percentage of nuclear MBNL1 was found to be 38.43% (N=3) and 36.63 %
(N=3) respectively (Fig. 3.8 and 3.9).
Western blot analysis therefore revealed that the DM cells show a greater
proportion of MBNL1 protein in the nuclear compartment compared to non-
DM cells. In both DM1 and DM2 cells the amount of nuclear MBNL1 was
found to be at least 50% greater than seen in non-DM cells.
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Type of extract Resuspension volume Volume loaded on W.B
Nuclear extract
(Normal and DM cells)
500 µl (RIPA buffer) 10 µl (equivalent to 4 x
10
4
nuclei)
Cytosolic extract
(Normal and DM cells)
500 µl (PBS) 10 µl (equivalent to 4 x
10
4
cytoplasms)
Table 3.2 Volumes used for representative loading during western
blotting.
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Figure 3.7 Distribution of MBNL1 in NIRA-Telo (control) fibroblast.
(A)Western blots showing separated sub-cellular fractions (Nuclear and
Cytosolic). MBLa (MBNL1) antibody recognises a band corresponding to
molecular weight of 41~42 kDa in all the triplicates. Controls for the
IUDFWLRQDWLRQ SURFHGXUH DUH VKRZQ E\ EORWWLQJ E\ /DPLQ% DQG ĮWXEXOLQ
antibody. (B) Histograms show data compiled from intensity scans of triplicate
samples, normalized against values for lamin-B and tubulin.
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Figure 3.9 The sub-cellular distribution of MBNL1 in DM1 cell line. (A)
Western blots showing the distribution of MBNL1 in nuclear (N) and cytosolic
(C) compartments of cell line KB-Telo MyoD (DM2). (B) Histograms show
data compiled from intensity scans of triplicate samples, normalized against
values for lamin-B and tubulin.
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3.3 Summary
In this chapter two different separation methods have been used to compare
the sub-cellular (Nuclear v/s Cytosolic) distribution of Muscleblind-like protein
1 in normal and DM cells. The first method uses Nonidet P-40 buffer and the
second method uses physical shearing method with a syringe to separate
nuclear and cytosolic fractions. MBNL1 protein appeared to predominate in
cytosolic fractions in both DM and non-DM cells after extraction with Nonidet
P-40 buffer but the sub-cellular distribution of MBNL1 appeared different after
physical shearing method, with a significant amount of MBNL1 present in
nuclear fractions. This may suggest that the detergent treatment might be
affecting the sub-cellular distribution of protein. Increased nuclear presence is
consistent with the current RNA model for DM pathogenesis which states that
the MBNL proteins are sequestered in the nucleus by the expanded
CUG/CCUG repeats forming foci in DM cells. Thus, physical shearing method
to separate nuclear and cytosolic protein fractions was used for all further
studies.
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Chapter-4: Effect of compounds on Muscleblind-like
protein 1 distribution
4.1 Introduction
A popular model of DM pathogenesis suggests that MBNL proteins are
sequestered in nuclear foci by mutant RNA which results in its depletion from
the nucleoplasm and in turn causes misregulated alternative splicing of various
other transcripts. It would be hypothesised that MBNL1 protein sub-cellular
distribution would be restored to that of an unaffected cell following
reduction/disruption of RNA nuclear foci. Thus, I decided to use western blots
to examine the distribution of MBNL1 protein in nuclear and cytosolic
fractions of DM cells before and after treatment with compounds, identified
during the primary screen.
4.2 Effect of compounds on MBNL1 nucleo-cytosolic
distribution in DM1 fibroblasts.
Following the primary and secondary screens RO 31-8220, gemcitabine,
chromomycin A3, IMOX and hypericin were highlighted as best potential
compounds that remove nuclear foci. In order to assess whether they affected
other aspects of DM pathophysiology these compounds were subjected to
additional assays such as MBNL1 distribution in nuclear and cytosolic
compartments. Initial analysis revealed that in both DM1 and DM2 cells the
amount of nuclear MBNL1 was at least 50% greater than observed in the non-
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DM cells (Fig. 3.7, 3.8 and 3.9), consistent with protein sequestration by the
repeat expansion RNA in nuclear foci. Treatment with these 5 compounds
resulted in reduced total levels of protein in KB-Telo MyoD (fibroblast) cell
extracts. However, this reduction was equivalent in both nuclear and
cytoplasmic fractions following compound treatments.
The conditionally immortalized fibroblast derived from DM1 patients (KB-
Telo MyoD) were used for drug treatment. Cells were grown for 3-4 days in
high serum media, before they were treated with compounds for 2 days. After
exposing the cells for 2 days with compounds, the nuclear and cytosolic protein
was extracted using physical shearing method (Fig. 4.1).
Following a two day treatment of DM1 fibroblast cells with each compound
significantly reduced the proportion of nuclear MBNL1 compared to DMSO
treated cells. The MBNL1 protein distribution in treated DM cells resembled
that of non-DM cells with a much higher percentage in the cytoplasm, around
~80% and only ~20% in the nuclear fraction.
DM cells showed a greater proportion of MBNL1 in the nuclear fraction
compared to non-DM cells. In DM1 cells the amount of nuclear MBNL1 was
at least 50% greater than observed in non-DM cells (NIRA-Telo, control
fibroblast) (Fig. 4.2A-B). Treatment of DM1 fibroblasts (Fig. 4.2C-D) with
chromomycin A3, RO 31-8220 and hypericin significantly reduced the
proportion of nuclear MBNL1 compared to DMSO treated cells (Fig. 4.2B).
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Compound treatment of DM1 cells (Fig.4.3A-B) with gemcitabine and IMOX
also shifted that pattern observed in DM cells to be more like those observed in
non-DM cells i.e. they both significantly reduced the proportion of nuclear
MBNL1 compared to DMSO treated cells (Fig. 4.2B).
Compound treatment affected the distribution of MBNL1 protein compared to
DMSO treated KB-Telo MyoD cells (DM1 fibroblasts) (Fig. 4.4). Treatment
with chromomycin A3 (p=0.0046) significantly reduced the nuclear MBNL1
protein to 22.24 % compared to 39.92% in nuclear DMSO treatment. Similarly
there was a significant difference between nuclear RO 31-8220 treatment
(p=0.0004) and nuclear DMSO treatment. Also there was significant reduction
in nuclear MBNL1 protein in case of hypericin (p=0.0009) and gemcitabine
(p=0.0202) compound compared to DMSO control treatment. Statistical
analysis showed a significant reduction in nuclear MBNL1 protein in case of
IMOX compound compared to DMSO control (p= 0.0003), the nuclear
MBNL1 protein after IMOX treatment got reduced to 10.16%. * represents a
significant difference from the control DMSO (Students two tailed t test;
*P<0.05)
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4.3 Effect of compounds on MBNL1 nucleo-cytosolic
distribution in DMmyoblasts
In view of findings described in sections 4.1 and 4.2 that compound treatment
affected MBNL1 distribution in fibroblasts, I decided to test whether the same
affect was consistent in DM myoblast cells. Immortalized myoblast cells
(DM15) derived from DM patients were used for compound treatments. The
cells were first differentiated for 5 days into myotubes under low serum
conditions to stop them from proliferating. The differentiated cells were then
exposed to compound treatments for 2 days. After 2 days of exposure the
protein was extracted to give the nuclear and cytosolic fractions (Fig. 4.5).
Western blot shows that DM15 myoblasts (DM) have a greater proportion of
MBNL1 in the nuclear fraction compared to Me16 (non-DM) myoblast cells.
In DM15 myoblast cells the amount of nuclear MBNL1 was much greater than
observed in Me16 myoblast cells (non-DM, control myoblast) (Fig. 4.6A-B).
Treatment of DM15 myoblasts (Fig. 4.6C, 4.7A-D) with compounds
chromomycin A3, gemcitabine, IMOX, RO 31-8220 and hypericin resulted in
a very significant shift of the ratio of nuclear to cytoplasmic MBNL1 (Fig.
4.6B).
In case of chromomycin A3 (p= 0.0129) and RO 31-8220 (p=0.0035), the
nuclear MBNL1 was reduced to 21.73% and 4.17% respectively compared to
38.40 % MBNL1 in nuclear DMSO treatment in DM15. Statistical analysis
showed a significant reduction of nuclear MBNL1 protein after the treatment
with compounds hypericin (p=0.0033), gemcitabine (p=0.0321), IMOX
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4.4 Comparing the effects of Ro 31-8220 and GF 109203X
Two of the 80 compounds from the kinase inhibitor library; GF 109203X and
Ro 31-8220 were identified as PKC inhibitors, although structurally very
similar but they had different effects on nuclear foci. Both being highly potent
PKC inhibitor, a similar effect would be expected but Ro 31-8220 was
effective at removing nuclear RNA foci whereas GF 109203X had only a slight
effect at the highest concentrations. It showed no effect at concentrations lower
than 40 µM (Ketley et al., 2013). Thus, I decided to compare its effect on the
distribution of MBNL1 protein in nuclear and cytosolic compartments.
Consistent with its effect in the nuclear foci assay, GF 109203X treatment did
not reduce or remove nuclear MBNL1 protein as shown by western blots
(Fig.4.9). Statistical analysis showed there was no significant difference
between treatments of GF 109203X and mock control DMSO.
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4.5 Effect of compounds on the MBNL1 protein in the foci
(MBNL foci)
The accepted model of DM suggests that the expanded repeat RNA leads to the
sequestration of RNA binding protein like Muscleblind-like protein 1
(MBNL1), which prevents MBNL1 from performing its other normal cellular
functions in the nucleus or cytoplasm. Indeed MBNL has been shown to co-
localize with expanded CUG and CCUG repeat RNA (Fardaei et al., 2001). To
examine the effect of compound treatment on the MBNL1 protein content of
nuclear foci, immunocytochemistry of DM cells before and after exposure to
compounds was performed. Immunocytochemistry was carried out using the
MBLa antibody, a mouse monoclonal antibody against MBNL1.
Immunofluorescence analysis in fibroblast cells from DM1 patients (KB-Telo
MyoD) showed MBNL foci within nuclei (Fig 4.10). It would be
hypothesized that if compounds can restore the MBNL1 protein distribution
then they might be able to reduce or remove the MBNL1 foci which is
primarily composed of sequestered MNBL1 protein in the DM1 patients cells.
Consistent with their effect on nuclear RNA foci and depletion of MBNL1
from the nuclear compartment of DM cells, the MBNL1 foci disappeared or
got reduced significantly following compound treatment.
Compounds R0 31-8220 and chromomycin A3 resulted in significant reduction
in number of MBNL1 foci in KB-Telo MyoD cells after the treatment when
compared to untreated KB-Telo MyoD cells (Fig. 4.11).
Also the cells treated with compounds hypericin and IMOX either lack or have
much reduced numbers of MBNL1 foci, as seen in immunofluorescence
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images (Fig. 4.12 and 4.13). Though no obvious reduction was observed in
case of GF109203X treatment, which is consistent to its effect on RNA nuclear
foci and MBNL1 sub-cellular distribution.
Statistical analysis revealed there was no significant effect of GF109203X and
gemcitabine treatment on MBNL1 foci in comparison with controls (DMSO
treated cells). However, the compounds hypericin (p=0.0001) and IMOX
(p=0.0001) showed a significant difference compared to controls (DMSO
treated). A very siginificant difference was observed in case of chromomycin
A3 (p<0.0001) and R0 31-8220 (p<0.0001) compounds as compared to the
DMSO treated cells (Fig. 4.14).
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Figure 4.14 Effect of compounds on MBNL1 foci. Histograms show data
compiled from the immunocytochemistry images after compound treatments in
KB-Telo MyoD cells. * represents a significant difference from the control
untreated (Students two tailed t test; *P<0.05).
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4.6 Immunocytochemistry studies on LR-Telo MyoD before and
after compound treatment
Two of the compounds identified; gemcitabine and hypericin appeared toxic in
the nuclear foci assay. Their toxicity profiles matched the reduction of foci,
whereas compounds RO 31-8220, chromomycin A3 and IMOX reduced foci in
the nuclear foci assay at concentrations that did not match the toxicity profile
(Ketley et al., 2013). Chromomycin A3 reduced the foci and didn't affect the
cell viability over 2 day exposure, whereas RO 31-8220 had a higher toxicity
profile in general but showed a sharper reduction in foci number over a narrow
concentration range. Similarly for IMOX, the toxicity profile didn't match the
reduction of foci. Thus, RO 31-8220, chromomycin A3 and IMOX were
selected for further analysis for immunocytochemistry studies in another DM1
cell line derived from a different patient, LR-Telo MyoD. Consistent with their
effect on KB-Telo MyoD cell line, RO 31-8220, chromomycin A3 and IMOX
were able to reduce MBNL1 foci compared to DMSO treated LR-Telo MyoD
cells (Fig. 4. 15).
Following the treatment with compounds RO 31-8220, chromomycin A3 and
IMOX, there was a significant reduction in the MBNL1 foci number over the
dilution range. Immunocytochemistry study of 12 point dilution series with a
1:3 dilution protocol, ranging from 200 pM to 40 µM concentration at series of
time intervals (2, 4, 8, 16, 24 and 48 hours after compound exposure) for
compounds chromomycin A3, IMOX and Ro 31-8220 was performed in LR-
Telo MyoD cells (DM1). In Figures 4.16- 4.18, foci number is represented
relative to the DMS
x axis.
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Figure 4.16 Standard concentration curves showing the effect of
chromomycin A3 treatment in LR-Telo MyoD cells. Chromomycin A3
treatment showing reduction in protein foci in 12 point titration ranging from
200pM to 40 µM in triplicates to determine its concentration response on
reduction of MBNL1 protein foci at different time intervals after compound
exposure
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Figure 4.17 Standard concentration curves showing the effect of RO 31-
8220 treatment in LR-Telo MyoD cells. RO 31-8220 treatment showing
reduction in protein foci in 12 point titration ranging from 200pM to 40 µM in
triplicates to determine its concentration response on reduction of MBNL1
protein foci at different time intervals after compound exposure
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Figure 4.18 Standard concentration curves showing the effect of IMOX
treatment in LR-Telo MyoD cells. IMOX treatment showing reduction in
protein foci in 12 point titration ranging from 200pM to 40 µM in triplicates to
determine its concentration response on reduction of MBNL1 protein foci at
different time intervals after compound exposure
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4.7 Effect of MBNL1/2 down regulation on the nuclear foci in
DM cells
The aim of this study was to establish whether MBNL1/2 depletion via RNA
interference would result in reduction of the nuclear foci as previously reported
by Dansithong et al. (2005) and to test the role of MBNL1 and MBNL2 in
formation of DM foci. MBNL1 and MBNL2 double knockdown was conducted
three times over a 7 day period using siRNA oligonucleotides to ensure
removal of MBNL. DM1 fibroblasts were transfected with siRNAs directed
against both MBNL1 and MBNL2, on days 0, 3 and 6 and after the 3 rounds of
knockdown, total protein was extracted which was subjected to Western blot
analysis for validation of successful knockdown. At the same time nuclear and
cytoplasmic RNA was also extracted for RT-PCR analysis and Bpm1
polymorphism assessment which will be discussed later in section 4.8. In situ
hybridization and immunocytochemistry studies were also performed on cells
to assess the effect of MBNL1/2 down regulation on both RNA nuclear foci
and MBNL (protein) foci in KB-Telo MyoD cells (DM cells).
12 µg of protein was subjected to SDS-PAGE followed by Western blot with
anti-MBNL1 and anti-MBNL2 monoclonal antibodies to measure the %
silencing achieved for both. In case of MBNL1, the % silencing achieved was
99% when compared to SCR (scrambled) or untreated cells whereas ~98%
silencing was achieved in case of MBNL2 knockdown (Fig. 4.19). Both the
blots were also probed with tubulin as an internal control for loading.
In contrast to results reported by Dansithong and colleagues (2005), there was
no reduction in the nuclear (RNA) foci number compared to SCR or untreated
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cells in knockdown experiment that I conducted (Fig. 4.21). The results from
the in situ hybridization images showed that there was a significant increase
(p=0.0005) in the number of smaller nuclear RNA foci after the MBNL1 and
MBNL2 knockdown as compared to SCR (scrambled) or untreated cells (Fig
4.20). Data for foci area and intensity were also obtained in the form of excel
spreadsheets. The histograms in figure 4.22 show data compiled for average
pixel intensity and average foci area for a single RNA foci after MBNL1 and
MBNL2 knockdown.
siRNA- mediated down-regulation of MBNL1 and MBNL2 resulted in a 40%
increase in the number of nuclear RNA foci than observed in scrambled siRNA
treated cells or untreated cells (Fig. 4.21). However, the average intensity and
the average area for single focus decreased significantly following MBNL1 and
MBNL2 knockdown compared to untreated cells (Fig 4.22).
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Figure 4.21 Histograms show data compiled from the in situ hybridization
images after MBNL1 and MBNL2 knockdown. Data suggests that there was
a significant increase (p=0.0005) in the number of nuclear RNA foci after the
MBNL1 and MBNL2 double knockdown when compared to SCR (scrambled)
or untreated cells. * represents a significant difference from the control
untreated (Students two tailed t test; *P<0.05, where N.S denotes data not
significant.
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Figure 4.22 Histograms show data compiled for average pixel intensity
and average foci area for a single nuclear RNA foci after MBNL double
knockdown. A significant reduction in the average area and average intensity
was observed for a single foci following MBNL double knockdown. *
represents a significant difference from the control untreated (*P<0.05).
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In a second set of experiment I attempted to assess the effect of MBNL1 and
MBNL2 down-regulation on MBNL1 (protein) foci. Immunocytochemistry
data shows that MBNL double knockdown in DM1 cell line (KB-Telo MyoD
cells) resulted in a significant reduction of MBNL1 (protein) foci compared to
SCR (scrambled, non-specific siRNA) or untreated cells as shown by
immunofluorescence images (p=0.0001) (Fig. 4.23). Though the western blot
data indicates 98% removal of MBNL protein, we still see the presence of a
few MBNL (protein) foci in the immunocytochemistry images, which may be
due to the residual 2% MBNL protein in the cells before the MBNL double
knockdown.
Statistical analysis showed there was a significant reduction in the average area
and average intensity of a single foci (MBNL foci) following MBNL double
knockdown as seen in figure 4.24.
Figure 4.23 Effe
foci. (A) Immunost
MBNL1 (protein)
(B-C) while scra
have any effect on
Histograms show
represents a signi
tailed t test; *P<0.05)
120
ct of MBNL1 and MBNL2 double knockd
aining with MBNL1 (MBLa) antibod
foci after MBNL1/2 knockdown, marked w
mbled knockdown which is non-specific to
nuclear foci in DM1 fibroblasts (KB-Telo
data compiled from the immunocytoche
ficant difference from the control untreate
.
F
o
c
i
n
u
m
b
e
r
M
B
N
L
1/
2
K
D
SC
R
own on MBNL1
y reveals fewer
ith white arrows.
MBNL does not
MyoD cells). (D)
mistry images. *
d (Students two
am
bl
ed U
N
121
Figure 4.24 Histograms show data compiled for average foci area and
average pixel intensity for a single MBNL (protein) foci after MBNL
double knockdown. A significant reduction in the average area and average
intensity was observed for a single foci following MBNL double knockdown
compared to scrambled or untreated cells. * represents a significant difference
from the control untreated (Students two tailed t test; *P<0.05, where N.S
denotes data not significant.
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4.8.1 Effect of MBNL1 and MBNL2 down-regulation on the mutant repeat
expansion transcript.
To determine the effect of MBNL1 and MBNL2 down-regulation on the
mutant repeat expansion transcripts and whether it could affect the release of
mutant repeat expansion, I utilized the BpmI polymorphism assay.
The RNA was extracted from both nuclear and cytosolic fractions after siRNA-
mediated down regulation for MBNL1 and MBNL2 in KB-Telo MyoD cells.
RNA was then reverse transcribed which was followed by PCR using
oligonucleotides for DMPK at 28 cycles. 154bp amplicon was generated by
PCR amplification. The BpmI polymorphic site is present only in one of the
alleles (the mutant allele in DM cells) and is absent from the normal allele in
DM cells. Overnight digestion of the 154bp PCR-product with the restriction
enzyme BpmI gave two bands on 3% ethidium stained agarose gel, one at
154bp and other at 138 bp which represented the normal and mutant expanded
allele respectively.
Analysis of RNA from the DM cell line KB-Telo Myod showed that the
DMPK mutant transcript was still present in the nuclear fraction and there was
no sign of liberation of the mutant transcript in the cytoplasm following
MBNL1 and MBNl2 knockdown (Fig 4.27). However, the MBNL1 and
MBNL2 down-regulation resulted in a reduction in the relative proportion of
the mutant transcript in the nucleus of KB-Telo MyoD cells compared to
scrambled (SCR) or untreated cells. Analysis showed that the % proportion of
the mutant allele in the nucleus was 27.09, 47.74 and 48.06 for MBNL 1/2
knockdown, scra
gel.
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4.9 Effect of Antisense oligonucleotides (AONs) on MBNL1
protein distribution in DM myoblasts
In past studies, Antisense oligonucleotides (AONs) have been widely used for
gene-specific knockdown in disorders that involve RNA or protein gain-of-
function effects. Various strategies like RNA interference (RNAi), antisense
oligonucleotides and steric-blocking oligonucleotides have been employed to
degrade or eliminate expanded (C/CUG)n transcripts.
It has already been shown that the hairpin structure formed by the expanded
(CUG)n repeats (Broda et al., 2005; Napierala and Krzyzosiak, 1997) can be
targeted by the RNA interference (RNAi) pathway (Malinina, 2005; Mooers et
al., 2005). Langlois et al. (2005) showed that normal DMPK transcripts in
cytoplasm and mutant transcript in nucleus in DM1 cells got reduced after
treatment with short hairpin RNA that targeted sequences in the 5` end of the
RNA. Also there has been evidence of silencing of expanded DMPK transcript
OHYHOV DQG UHGXFWLRQ LQ QXPEHU RI ULERQXFOHDU DJJUHJDWHV E\ D ƍ2PHWK\O
phosphorothioate modified (CAG)7 AON (Mulders et al., 2009). In 2012,
Wheeler et al. published a paper in which they described a gapmer with 2-O-
methoxyethyl modification at both ends with a central gap of 10 unmodified
nucleotides which was able to reduce CUG
exp
RNA level by inducing RNase H
activity. It also resulted in release of sequestered MBNL1 protein and an
improvement in MBNL1 dependent splicing abnormalities (Wheeler et al.,
2012) There is some published data on splice switching which lead to the
correction of ClC-1 splicing in mouse models of myotonic dystrophy by steric-
blocking AON (Wheeler et al., 2007)
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We initially found that two types of chemically modified oligonucleotides
(CMOs) : PNA and 2OMe, were readily taken up by DM cells, via gymnotic
delivery, and removed nuclear RNA foci at nanomolar concentrations, in a cell
based assay, which uses high content imaging to visualise the number, size and
intensity of foci (data not included). So I decided to assess the effect of one of
the antisense oligonucleotides (AONs), PNA, on MBNL1 protein distribution
in DM myoblasts. I conducted western blots to quantify results of experiments
with 21-mer PNA.
DM15 cells were treated with 21-mer CAG7 PNA to look at its effect on
MBNL1 distribution before and after the treatment. Treatment with PNA at
two different concentrations caused a significant reduction in nuclear MBNL1
protein compared to nuclear protein level in the untreated DM15 cells (Fig.
4.29 and 4.30). It was observed that the treatment shifted the pattern to the one
observed in wild type myoblast cells (Me16 cells, Non-DM) (Fig. 4.28).
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Figure 4.30 Histograms showing the sub-cellular distribution of MBNL1
before and after treatment with PNA Histograms show data compiled from
intensity scans of triplicate blots for myoblast cell line DM15, normalized
against values for lamin-B and tubulin following treatment with PNA. Me16 is
the Non-DM cell line, which served as control cell line. All the statistical
comparisons are done to the DM15 untreated sample. * represents a significant
difference from the control DMSO (Students two tailed t test; *P<0.05)
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4.10 Summary
Tertiary assays were developed and applied in this chapter to validate the
positive hits compounds that were highlighted in primary screens. Compounds
were subjected to further analysis involving western blotting, to examine the
effect of treatment on sub-cellular distribution. The data from the western blot
suggests that the compounds chromomycin A3, hypericin, RO 31-8220,
gemcitabine, IMOX significantly altered the ratio of nuclear to cytoplasmic
MBNL1 compared to that observed in DMSO treated cells with ratios being
more similar to those observed in non-DM cells.
Consistent with their effect on RNA foci and the depletion of MBNL1 from the
nuclear compartment of DM cells, all the compounds (apart from gemcitabine)
also significantly reduced the MBNL (protein) foci from DM1 cells after
treatment compared to DMSO treated controls.
Studies were also conducted to down regulate the MBNL1 and MBNL2 in DM
cells to test whether MBNL1/2 depletion would result in reduction of the
nuclear foci. MBNL1 and MBNL2 double knockdown resulted in a 40%
increase of nuclear RNA foci than observed in scrambled siRNA treated cells
or untreated cells, though a significant reduction in size was observed in case
of MBNL (protein) foci as shown by immunocytochemistry images.
MBNL 1 and MBNL2 down regulation did not result in the release of mutant
transcript from the nucleus to the cytoplasm in KB-Telo Myod (DM) cells.
However, it had a degradative effect on the mutant DMPK transcript.
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Chapter -5: The role of Protein Kinases in DM
5.1 Introduction
Our lab has developed a cell based screening assay that allows us to determine
the effect of compounds on RNA nuclear foci. A series of small molecule
libraries were screened as part of this primary assay. The kinase inhibitor
library used in the primary screening assay gave two compounds (Ro 31-8220
and Hypericin) that were capable of reducing nuclear foci. Both of these
compounds are PKC inhibitors. But screening of other PKC inhibitors showed
no effect on nuclear RNA foci. An extended screen of kinase inhibitors
identified a compound IMOX which could also remove nuclear foci, an
inhibitor of PKR, a double stranded RNA-activated kinase. The data provides
strong support for the involvement of a kinase in DM pathophysiology,
however the target of these compounds still remains elusive.
5.2 Protein kinases in Myotonic Dystrophy
Kinase involvement in the DM has been described previously, with particular
interest in PKC. Published data suggests that PKC is activated in the presence
of expanded CUG repeat containing RNA (Wang et al., 2009) . PKC activation
leads to phosphorylation of CUGBP protein, which extends the half life of the
protein leading to its increased levels, which in turns leads to CUGBP
dependant splicing misregulation (Kuyumcu-Martinez et al., 2007). Compound
R0 31-8220 has also been tested on an inducible DM1 mouse model where it
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LQKLELWHG 3.& Į DQG ȕ,, ,QKLELWLRQ RI WKHVH LVRIRUPV OHDGV WR UHGXFWLRQ RI
CUGBP1 hyperphosphorylation and reduced protein levels as reported by
Wang and colleagues (2009).
Identification of R0 31-8220 and hypericin as positive hits in the primary
screening was encouraging as role of RO 31-8220 has already been described
in context of CUGBP protein. Unlike MBNL1, CUGBP1 does not colocalize
with RNA nuclear foci (Jiang et al., 2004; Mankodi et al., 2005) so therefore
the reduction of nuclear foci in DM patients cells following RO 31-8220
treatment suggests there may be other mechanisms involved like
phosphorylation of MBNL1 protein?
The hypothesis that MBNL may be a target of a kinase pathway also predicts
that phosphorylation of the protein may play an important role. MBNL1 is a
shuttling protein and shuttles between the nucleus and cytoplasm in unaffected
cells. MBNL is sequestered in the nuclei of DM cells after binding to the repeat
expanded RNA. It could be hypothesised that following inhibition of the kinase
via RO 31-8220, the protein becomes unphosphorylated which prevents it from
shuttling back to the nucleus and therefore prevents its sequestration by repeat
expanded RNA in the nuclear foci. To test this, I decided to perform
phosphorylation experiments using phospho-specific antibodies to test whether
MBNL1 exists in phosphorylated state and what happens to its phosphorylated
state following treatment with the protein kinase inhibitors.
Protein phosphorylation plays a important role in signal transduction in many
cells (Hunter, 1995). Many proteins are activated upon phosphorylation, and
the phosphorylation state of a protein has frequently been taken as a measure of
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its activation state. Protein phosphorylation is a post-translational modification
(PTM) of a protein in which a serine, a threonine or a tyrosine residue is
phosphorylated by a protein kinase by addition of a phosphate (PO4
3-
group).
Within a protein, the most common phosphorylation that can occur is on serine
residue, followed by threonine. Tyrosine phosphorylation is relatively rare.
Several antibodies can be used to detect whether a protein is phosphorylated or
unphosphorylated at a particular site. Antibodies that bind to and detect
phosphorylation-induced conformational changes in the protein are called
phospho-specific antibodies. I have used western blotting and phospho-specific
antibodies in immunoprecipitation assays to investigate if MBNL1 protein is
phosphorylated and at which residue.
Figure 5.1 shows western blots probed with phospho-serine antibody after
performing immunoprecipitation using anti-MBNL1 antibody (MBLa Ab.).
The band marked with white star represents MBNL1 phosphorylated band at
serine residue.
Figure 5.2 shows western blots probed with phospho-threonine and phospho
tyrosine antibodies after performing immunoprecipitation pull down
experiment with anti-MBNL1 antibody. There was no evidence for
phosphorylation of MBNL1 protein at threonine or tyrosine residues.
These pull down experiments showed that MBNL1 protein is indeed
phosphorylated at serine residue but there was no evidence of phosphorylation
at threonine or tyrosine residues from these experiments.
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5.3 MBNL1 phosphorylation studies
A variety of techniques can be used for detecting (or mapping) phosphorylated
sites. In the view of findings in section 5.2, I have attempted to map the
phosphorylated site (s) in MBNL1 protein using MS (Mass spectrometry) in
combination with immuno-precipitation (IP).
5.3. 1 Immunoprecipitation of MBNL1 and Interacting proteins
The protocol for identification of MBNL1 is summarized in Fig 6.7. Proteins
were extracted from NIRA-Telo (non-DM fibroblast) cells. Proteins were then
quantified using the Bradford method (Bio-Rad). MBNL1 was
immunoprecipitated from 5 mg of total proteins, using antibodies bound on
magnetic beads according to the Dynal beads protocol (as described in section
2.5.3). Immunoprecipitated proteins were rinsed three times with washing
buffer, before boiling for 5mins in LDS buffer. Immunoprecipitated proteins
were loaded and resolved on 10% polyacrylamide gel and finally stained with
colloidal Coomassie. Band of interest (marked red in Fig.5.3B) was excised
and sent for protein identification by Mass spectrometry. The protein bands of
interest were trypsin-digested and analysed on MALDI-TOF and MS-MS. The
mass spectrometry analysis was carried out by BSRC Mass Spectrometry and
Proteomics Facility in University of St Andrews.
Before sending the excised sample for mass spectrometry analysis, I decided to
do a validation study on the excised band from the Coomassie stained gel. One
of the excised bands (marked yellow in Fig.5.3B) was resolved on 10%
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polyacrylamide gel again and probed with anti-MBNL1 antibody to validate
the presence of MBNL1 protein in excised samples.
The proteins identified by Mass Spec were ACTB (Actin, cytoplasmic 1,
(Beta-Actin)), Actin 11, Synembryn (protein Ric-8), Serine/threonine- protein
kinase TEL1 and Actin 1 (Fig.5.4). Muscleblind-like protein 1 (MBNL1) was
not identified by mass spectrometry studies and result showed that ACTB
(Actin cytoplasmic 1, Beta-Actin) was the major contaminant in the excised
band.
The majority of proteins identified in IP-experiment were non-specific binders.
Several additional steps were employed like pre-clearing the lysate before IP,
adjusting the washing buffer stringency to reduce background or non-specific
binding. But none of these steps were able to reduce the non-specific binding
or Actin contaminants. So the data described here was inconclusive and
additional experiments must be conducted to map the phosphorylated site (s) of
MBNL1 protein.
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Figure 5.4 Proteins identified by mass spectrometry after the MBNL1 IP.
Beta-Actin was identified as the major contaminant in IP because it came up
with the highest score (93%) in the result window.
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5.4 siRNA knockdown of isoforms of Protein Kinase C (PKC)
5.4.1 Introduction
Although the initial analysis suggested that Ro 31-8220 may not be acting via
PKC, this was verified by performing knockdown of the PKC isoforms to
ascertain the link between the presence of foci and PKC activity. It would be
hypothesised that knockdown of a kinase target by siRNA should also remove
or reduce nuclear foci if the kinase is the true target of the inhibitor
compounds. SiRNAs targeting the kinase of interest was tested in the nuclear
foci assay in DM cell lines (KB-Telo MyoD). Western blotting was also
performed to confirm the level of knockdown for various PKC isoforms.
PKC also known as Protein kinase C, is a family of protein kinase enzymes
that are involved in controlling the function of various other proteins through
the phosphorylation of hydroxyl groups of serine and threonine amino acid
residues on these proteins. PKC enzymes are activated by increase in
concentration of of diacylglycerol (DAG) or calcium ions (Ca
2+
). Different
isoforms of PKC have been discovered which can be divided into three
subfamilies or groups (Mellor and Parker, 1998), based on signals they require
IRUDFWLYDWLRQ WKHFODVVLFDORUFRQYHQWLRQDO LVRIRUPVĮȕ,ȕ ,,Ȗ  WKH
QRYHO3.& LVRIRUPVİșįȘ DQG WKHDW\SLFDO3.& LVRIRUPVȗDQGȜ
(Nishizuka, 1995). The conventional isoforms requires Ca2+, DAG, and a
phospholipid such as phosphatidylserine for activation. The novel PKC
isoforms requires require DAG, but do not require Ca2+ for activation. Thus,
classical and novel PKCs isoforms are activated through the same signal
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transduction pathway as phospholipase C. But atypical isoforms requires
neither DAG nor Ca
2+
for their activation.
5.4.2 siRNA knockdown of PKC isoforms.
In order to validate PKC as potential therapeutic target for myotonic dystrophy
I conducted knockdown screens using siRNAs in KB-Telo MyoD cells
corresponding to each of the isoforms of PKC. The isoforms included were
3.&Į DOSKD 3.&ȕ EHWD 3.&Ȗ JDPPD 3.&į GHOWD DQG 3.&İ
(epsilon).
:HVWHUQEORWVVKRZHGFOHDUUHGXFWLRQLQSURWHLQOHYHOVLQFDVHRI3.&Į3.&į
DQG3.&İ7KHUHZDVQRHYLGHQFHRINQRFNGRZQLQFDVHRI3.&ȕDQG3.&Ȗ
(data not included) which might be due to different expression levels in
different organs or cell types. Expression of most of the PKC isoforms is
ubiquitous and only some of them are localized to specific tissues. For
H[DPSOH 3.& Ȗ KDV EHHQ VKRZQ WR EH VSHFLILFDOO\ H[SUHVVHG LQ &16 DQG
VSLQDO FRUG QHXURQDO WLVVXHV ZKHUHDV 3.&ȕ LV SUHVHQW LQ SDQFUHDWLF LVOHW
cells, brain and monocytes (Way et al., 2000).
Figure 5.5 and 5.6 shows siRNA mediated down-regulation of PKC alpha,
PKC epsilon and PKC delta isoforms. There was a significant reduction in
protein level after each knockdown.
Figure 5.7 shows the In situ merged images (DAPI+ Cy5) images for all PKC
isoforms after siRNA knockdown in KB-Telo MyoD cells. There was no
obvious reduction in foci number for any of the PKC isoforms compared to
untreated cells.
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5.5 IMOX
The other compound that was screened as part of primary screen was IMOX
(imidazolo-oxindole), which is an inhibitor of PKR (EIF2AK2, eukaryotic
translation initiation factor 2-alpha kinase 2) a double stranded RNA-activated
kinase. IMOX was able to eliminate foci and also resulted in redistribution of
MBNL1 protein after treatment in western blots. PKR is activated in response
to double-stranded RNA (dsRNA), the synthesis of which is caused virally. It
been shown that PKR can also be activated in presence of expanded CUG
repeat RNAs which form hairpins in DM (Tian et al., 2000). Once activated
3.5 DXWRSKRVSKRU\ODWHV ZKLFK WKHQ OHDGV WR WKH SKRVSKRU\ODWLRQ RI WKH Į
VXEXQLWRIHXNDU\RWLF LQKLELWLRQIDFWRUH,)Į7KLVIXUWKHU LQKLELWVFHOOXODU
mRNA translation and protein synthesis.
So to establish PKR as a target for DM therapy, I conducted knockdown
screen using siRNA corresponding to PKR to validate if it is the true target.
The siRNA knockdown for PKR did not produce a significant reduction in
nuclear foci in DM cells (Fig. 5.8C) suggesting that PKR cannot be used as a
potential drug for DM treatment.
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5.6 Summary
MBNL1 protein was found to be phosphorylated on serine residues following
western blotting with phospho-specific antibodies in combination with
immunoprecipitation assays. No phosphorylation of MBNL1 threonine or
tyrosine residues were found after probing with phospho-specific threonine or
tyrosine antibodies.
In a parallel line of investigation, mass spectrometry in combination with
immunoprecipitation assays was used to map the phosphorylated sites of
MBNL1 protein which resulted in the identification of actin as the major
contaminant in mass spectrometry analysis.
Finally, the knockdown of all PKC isoforms and PKR isoform showed no
obvious effect on RNA foci number reduction which suggested that they might
not be the true target and cannot be used as potential drug targets for DM
treatment.
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Chapter 6: Discussion and Conclusions
One of the earliest events in DM pathophysiology occurs when mutant
expanded RNAs are transcribed and accumulate in the nuclei of DM cells,
where they sequester MBNL proteins, forming spots or foci. Our own lab has
developed a cell based assay using an in situ hybridisation protocol to screen
libraries of potentially useful compounds or small molecules which could
eliminate nuclear foci. Four libraries were screened as part of the primary
screen (Ketley et al., 2013).
Compounds chromomycin A3, RO 31-8220, gemcitabine, IMOX and hypericin
reduced RNA nuclear foci in the primary and secondary assays. In order to
assess whether these compounds affected other aspects of DM
pathophysiology, I subjected them to additional assays like MBNL1 sub
cellular distribution and immunocytochemistry. Western blots were used to
examine the sub cellular distribution of MBNL1 protein in nuclear and
cytosolic fractions of DM cells before and after treatment with compounds,
identified during the screen.
Treatment with all the compounds produced a significant reduction in the
proportion of nuclear MBNL1 compared to DMSO treated cells in DM
fibroblast and myoblasts. The MBNL1 protein distribution in treated KB-Telo
MyoD cells (DM1 fibroblasts) resembled that of non-DM cells with a much
higher percentage in the cytoplasm (~80%) and only ~20% in the nuclear
fraction. Treatment of DM15 myoblast cells (~3000 CTG repeats) with these
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compounds also produced a redistribution of MBNL protein, with a significant
increase in the cytoplasm and a striking reduction in the nucleus compartment.
Nuclear foci consist of mutant repeat expansion RNA and muscleblind-like
proteins and most likely other proteins that are yet to be identified. It was
hypothesized that if compounds can restore the MBNL1 protein distribution (as
suggested by western blot data), they might be able to reduce or remove the
MBNL foci (MBNL1 protein in foci). Consistent with the observed reduction
of MBNL1 protein from nuclear compartment of DM cells after treatment. The
number of MBNL foci was also reduced significantly as observed in
immunocytochemistry images.
One possible explanation is that these compounds are either able to disrupt the
MBNL1 and repeat expansion RNA interaction in the nuclear foci via a
physical interaction (compounds outcompeting MBNL1 to bind to the repeat
expansion RNA) or by a functional response in which MBNL1 protein is
modified by a kinase targeted by the inhibitors (as might be in case of Ro 31-
8220, IMOX or Hypericin). It is possible that the nuclear/cytoplasmic
localization of MBNL1 protein is determined by a phosphorylation event
which is modified after the treatment with RO 31-8220. To assess this
possibility, phosphorylation studies were conducted to see whether MBNL1
exists in a phosphorylated state. IP Experiments were performed in
combination with phospho-specific antibodies. The data pointed towards a
phosphorylation event taking place. The MBNL1 protein was phosphorylated
at serine residue as observed in the blots probed with serine phospho-specific
antibodies. There was no evidence of phosphorylation at threonine or tyrosine
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residues from these experiments. In view of these findings, further experiments
were conducted to map the phosphorylated site (s) in MBNL1 protein using
MS (Mass spectrometry) in combination with immuno-precipitation (IP). Actin
came up with the highest score in the result window after mass spectrometry
analysis. It appeared to mask the levels of Muscleblind-like protein 1 such that
it was either difficult to identify low levels of MBNL1 or the sample somehow
got contaminated with actin proteins. Despite several attempts it was not
possible to overcome technical problems. Further enrichment experiments need
to be done to resolve this contamination issue. Thus it was difficult to map the
phosphorylated site and the data described here is difficult to interpret.
The underlying mechanism by which these compounds act on foci is not
known and requires further investigation. Two of the compounds identified in
the primary screens; gemcitabine and hypericin showed toxic profiles that
matched the disappearance of RNA foci, whereas Ro 31-8220, IMOX and
chromomycin A3 reduced foci numbers at concentrations that did not fully
match the toxicity effect (Figure 1.9). Thus, Ro 31-8220, IMOX and
chromomycin A3 were further studied.
Chromomycin A3 is a glycosidic antineoplastic antibiotic isolated from the
bacterium Streptomyces griseus that inhibits the DNA-dependant RNA
polymerase reaction by reversibly binding to guanine-cytosine (G-C) base pairs
in the minor groove of DNA to inhibit RNA synthesis (Kaziro and Kamiyama,
1965). It has been shown that chromomycin A3 interacts with GC rich regions
of duplex DNA (Berman et al., 1985; Chakrabarti et al., 2000), thus it is
possible that it also interacts with stem-loop structures present in expanded
repeat RNAs. This binding interaction could result in overall disruption of the
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hairpin structure, thus releasing the MBNL protein from the foci and restoring
the MBNL1 protein distribution (western blots data).
The other compound that was screened as part of a phosphatase and kinase
library was Ro- 318220, which is a known PKC inhibitor. Although it was
clear that Ro 31-8220 affected several aspects of DM pathophysiology, the
actual mechanism of its activity on foci is less clear. The preliminary structural
evidence suggests that Ro 31-8220 may not be acting via PKC. The
phosphatase and kinase library used in the primary screening contained many
other kinase inhibitors, some of them were also PKC inhibitors. But there was
an obvious difference in terms of effect on the nuclear foci, despite being
equally potent PKC inhibitors as Ro 31-8220 (Ketley et al., 2013). GF
109203X, a highly potent PKC inhibitor had very limited effect on the nuclear
foci (RNA foci) and several other downstream assays like MBNL1 protein
distribution and on MBNL1 protein foci essay. Structurally GF 109203X and
Ro 31-8220 are very similar to each other, so a similar effect would be
expected. But kinase inhibitors like Ro 31-8220 are notoriously promiscuous
and are capable of inhibiting multiple other kinases with the same potency as
PKC (Alessi, 1997). This suggests that another kinase may be involved and
specifically may be acting on MBNL in the foci. Indeed there has been
evidence of additional kinase involvement in response to repeat expansion
RNA in literature (Hernandez-Hernandez et al., 2006; Jin et al., 2009;
Timchenko et al., 2001) .
Nuclear foci comprise of repeat expansion RNA bound to muscleblind-like
proteins and possibly other proteins which are still not known. To test the
effect of the MBNL double knockdown on the RNA foci and MBNL (protein)
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foci, in situ hybridization and immunocytochemistry studies were performed.
In a parallel line of investigation to determine the effect of MBNL double
knockdown on the mutant allele, a BpmI polymorphism assay was also
employed, which allowed me to distinguish between the mutant and wild-type
transcripts. MBNL1 and MBNL2 down-regulation resulted in an increase in
the RNA nuclear foci number which would suggest that MBNL might play an
important role in maintaining the DM1 focus integrity. Thus, depletion of
MBNL from the cell causes the repeat expansions transcripts to disperse,
leading to an increase in number of (smaller) RNA nuclear foci. This was
further validated from histogram data compiled from the average intensity and
average area of RNA foci after MBNL double knockdown. The data showed
that the RNA foci were smaller in size and were of lesser intensity as compared
to RNA foci seen in untreated cells. However, the result obtained from my
study deviates from that reported by Dansithong and colleagues (2005) who
suggested that depletion of MBNL1 alone was sufficient to reduce the number
of RNA foci by ~70 %. The difference in results may be due to differences in
cell lines used in our experiment compared with those reported by Dansithong
et al (2005) in which DM myoblasts were used instead of DM fibroblasts.
Several RNA binding proteins and transcription factors like Sp1, STAT3,
67$7DQG5$5ȖKDYHEHHQUHSRUWHGLQSDVWWRLQWHUDFWZLWKH[SDQGHG&7*
repeat sequences in vivo (Ebralidze et al., 2004). Thus, one possible
explanation for the presence of smaller RNA foci after MBNL double
knockdown may be due to some other proteins which are still bound to the
mutant transcripts and therefore keeping it trapped in the nucleus.
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The data from the chapter 4 shows that following MBNL double knockdown,
the DMPK mutant transcript are still present in the nuclear fraction and there
was no sign of liberation of the mutant transcript to the cytoplasm. This may be
due to some intrinsic structural properties of the repeats. However, the MBNL1
and MBNL2 down-regulation resulted in a reduction in the relative proportion
of the mutant transcript in the nucleus of KB-Telo MyoD cells compared to
scrambled (SCR) or untreated cells. It may be possible that depletion of MBNL
from the cell renders the mutant RNA transcripts more prone to degradation.
Thus, in summary, I have reported that the compounds chromomycin A3,
gemcitabine, IMOX, RO 31-8220 and hypericin which were highlighted as part
of primary screening resulted in a very significant shift of the ratio of nuclear
to cytoplasmic MBNL1 in DM fibroblast and myoblast cells after treatment,
consistent with the observed reduction of MBNL protein in foci as seen in
immunocytochemistry studies. These compounds may provide the starting
point for future drug development studies for DM therapy. Also the
identification of RO 31-8220 in primary screen begs the question if there is a
link between the roles of MBNL1 and CUGBP in DM.
6.1 Future work and recommendations
At the time of writing this report, it was not possible to map the phosphorylated
site (s) of MBNL1 protein. Additional experiments such as 2-D gels need to be
incorporated after conducting IP pull down experiments (using MBNL1
antibody) to separate the MBNL1 protein and contaminants (mainly Actin)
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according to their iso-electric point (pH). This would allow us to excise
spot/band containing only MBNL1 protein and then analyse it on MALDI-TOF
and MS-MS for further mapping of the phosphorylated residue.
Also, we have reported a medium throughput assay using in situ hybridisation
and high content imaging to identify compounds that may provide the starting
point for future drug development studies for DM therapy. Target identification
represents an early stage in the drug development pathway but is critical to
establish a pharmaceutical collaboration to be able to conduct structure activity
relationship analysis against in vitro target selectivity. These compounds are
fairly toxic in our cell based assays. Thus, it is probably not suitable for human
administration. Further work is required to conduct a medicinal chemistry
programme to develop a suitable drug treatment for DM. In addition to the
medicinal chemistry, ADME and in vivo PK of lead compounds will be
outsourced via a pharmaceutical company. Continued medicinal chemistry-
driven optimization of lead series compounds and in vivo testing in a mouse
model of DM will be conducted in collaboration with colleagues in Paris.
Following compound treatment in the DM mouse model we will measure
specific strength measures like grip-test, treadmill, ankle dorsiflexion
extension. Restoring these measures will be important if a drug is to offer
potential therapeutic benefit to patients
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